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IV 
 
Summary 
 
 
 
Hydrogen sulfide (H2S) is now considered an important endogenous 
gasotransmitter able to play pivotal roles in the cardiovascular 
system, where it regulates homeostasis, by inducing relaxation of the 
vascular smooth muscle cells and cardioprotection, mainly by 
activating ATP-sensitive potassium channels. H2S is also capable to 
exert its activity in many other systems, such as the central nervous, 
respiratory, gastrointestinal and endocrine systems. H2S 
physiological levels are finely regulated by enzymatic and non-
enzymatic pathways, and significant changes of H2S-producing 
enzyme expression/activity have been associated with several 
pathological states. 
It is now accepted that H2S is involved in inflammation, although 
there are many controversial hypothesis on its roles: it is considered 
pro-inflammatory when it is present at high concentrations, but it 
elicits anti-inflammatory activities when the concentrations are 
lower.  
Mast cells are important cells related to inflammatory events and a 
rational strategy to reduce the inflammation process could be to 
reduce mast cell activation and the consequent release of pro-
inflammatory mediators from their internal granules. Yet, the 
influence of endogenous H2S and of H2S-releasing drugs on these 
cells has been poorly investigated to date.   
Accordingly, a pharmacological modulation of this gasotransmitter is 
becoming a challenging research field in drug discovery. In 
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particular, H2S-donors, molecules able to release H2S and restore its 
impaired production, appear to be a promising class of drugs.  
This PhD thesis presents new results in the discovery of novel H2S-
donors, both of natural and synthetic origin, belonging to different 
chemotypes, and the evaluation of their effects on mast cell 
degranulation and in mast cell-mediated cardiac injury. In a first 
phase, a wide array of H2S-releasing compounds was probed; 
compounds exhibiting the most interesting profile were selected for 
subsequent studies. 
After that, possible anti-degranulating effects of H2S were tested on 
three different cell lines, RBL-2H3 (rat basophilic leukemia cells), 
BMMC (bone marrow-derived mast cells) and HMC-1 (human 
mastocytoma cells) degranulated by different stimuli (antigenic and 
non-antigenic). This part of the study revealed significant inhibitory 
effect of H2S-releasing drugs on the mast cell degranulation of all the 
mast cell line, indicating that: a) endogenous H2S may play 
significant roles in modulating mast cell degranulation, and thus in 
influencing mast cell-mediated inflammatory processes; b) H2S-
releasing drugs may be useful in treating pathological situations 
associated with mast cell degranulation. 
Recently, it has been demonstrated that cardiac mast cells, closely 
located to the nerve endings, are a previously unrecognized source of 
renin, which is stored and released from intracellular granules. 
Released renin activates a local renin-angiotensin system (RAS) and 
promotes norepinephrine (NE) release from sympathetic nerve 
endings, culminating in severe cardiac dysfunction.  
In particular, mast cell degranulation is elicited by 
ischemia/reperfusion (I/R) injury and is correlated to the severity of 
the I/R damage. Since the cardioprotective activity of H2S in the 
cardiovascular system is widely reported, but its mechanisms are 
still largely unexplored, the last phase of the experimental work 
investigated the possible relation between H2S-induced 
cardioprotection and inhibition of heart mast cell degranulation in 
rat and mouse models of myocardial I/R. The preliminary results of 
this phase show: a) that the selected H2S-releasing compound failed 
to inhibit mast cell degranulation and renin release when induced by 
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I/R; b) the H2S-releasing compound significantly reduced NE release. 
In addition, other cardiac parameters indicating the functionality of 
the heart were measured, such as rate pressure product (RPP), 
expressed as product of heart rate (HR) and left ventricular 
developed pressure (LVDP), arrhythmias duration (VT/VF) and 
coronary flow (CF). Although those factors were restored to basal 
levels by the H2S-donor both in rat and murine models of I/R, the 
obtained results suggest that cardioprotection might not be linked to 
inhibition of mast cell degranulation. 
Indeed, when a selective blocker of mitochondrial ATP-sensitive 
potassium channels (mitoKATP), was used in the presence of the H2S-
donor, a clear antagonism was observed on the anti-ischemic effect 
of the H2S-donor. This preliminary result indicates the important 
role in cardioprotection of the H2S-releasing compound and confirms 
the hypothesis of a possible mechanism on mitochondrial ion 
channels. 
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Chapter 1 
 
Introduction 
 
1.1. History of hydrogen sulfide 
Since the discovery of their existence, endogenous gasotransmitters 
have been widely and closely explored. The term gasotransmitter 
encompasses intrinsic features of a molecule such as its small 
volume, its ability to freely permeate membranes without activating 
any receptors, their capability to auto-regulate their generation, 
their ability to modulate biological pathways/functions at a 
physiological concentration, and the presence of specific biological 
targets[1]. Another characteristic profile of gasotransmitters is the 
short half-life and their potential toxicity at high concentrations[2]. In 
the last decades rigorous studies were carried out on endogenous 
gaseous molecules acting as important modulators in human 
signaling pathways. The most and widely recognized molecules are 
carbon monoxide (CO) and nitric oxide (NO), both endogenously 
produced in the human body. In addition to those two gaseous 
compounds, hydrogen sulfide (H2S) has been newly discovered in 
human tissues as an important mediator in cellular physiology and 
pathology. It is involved in several processes and it is able to mediate 
several effects in many districts although it exerts its role mainly in 
the nervous and cardiovascular systems[1]. 
In the past, it was only known for its toxicity at quite high 
concentrations and for its typical pungent odor of rotten eggs: 
 
 
2 
 
indeed it is well detectable by the human nose at concentrations 
lower than the toxic ones. 
Nevertheless, the discovery of endogenous sulfides in mammalian 
brain first suggested that H2S might have a physiological role[3,4]. 
Given that H2S was initially considered to be toxic, its cytoprotective 
effects were overlooked. The pioneering studies reported by the 
research group led by the neuroscientist Hideo Kimura determined 
that at physiologic concentrations H2S enhances N-methyl-D-
aspartate receptor-mediated responses and facilitates the induction 
of hippocampal long-term potentiation. This has opened up a new 
perspective on H2S as a gasotransmitter[5]. Thus, H2S is now 
considered as the third member of the family of gasotransmitters 
and is emerging as a novel and increasingly important biological 
mediator, that has attracted much investigative attractions [5] (Fig. 
1). 
 
 
Fig. 1. History of the emergence of hydrogen sulfide (H2S) as a physiological 
regulator of neural and cardiovascular homeostasis. H2S is believed to be 
responsible for mass extinctions that occurred over 250 million years ago as toxic 
gases were spewed from deep in the earth. In the 1700s, H2S was linked to injuries 
sustained by sewer workers. In 1989, H2S was detected in the brain of mammals 
by several groups. In 1996-1997, H2S was shown to modulate vascular tone and 
neuronal function. Finally in 2002, H2S was implicated in vascular function and 
blood pressure regulation in seminal studies. H2S was then shown to post-
translationally modify proteins via s-sulfhydration by Dr. Solomon Snyder’s 
group[6]. Adopted from Hideo Kimura[5]. Savage and Gould[7], Goodwin et al.[3], 
Warenycia et al.[4], and Mustafa et al.[8]. 
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At low concentration, H2S is widely recognized as a regulatory 
signaling molecule which influences physiological and pathological 
functions in mammalian tissues[9-11].   
In contrast, at relatively high concentrations H2S can promote 
potentially lethal effects by compromising mitochondrial respiration 
and being involved in other pathological conditions, such as 
inflammation, sepsis, and stroke[12]. 
Presently, NO has been undoubtedly the most widely investigated 
and characterized among these three endogenous gases. Several 
studies have clarified its multiple physiological roles and 
mechanisms of action, and many molecules able to release NO have 
been proposed as new pharmacotherapeutic tools[13,14]. In contrast, 
CO seems to have little chance of pharmacological development, 
because of its high toxicity and scarce manageability. Early studies 
on H2S indicate that this gasotransmitter might represent a truly 
attractive candidate in the field of endogenous gaseous modulators; 
in fact, it possesses almost all the beneficial cardiovascular effects 
exhibited by NO and it shares also anti-inflammatory effects, but H2S 
diverges from NO by not contributing to the formation of deleterious 
reactive oxygen species (ROS) typical of NO. In fact, this molecule 
showed an antioxidant profile typical of organic and inorganic 
sulfides, behaving as a scavenger of ROS[15,16].  
H2S elicits physiological effects on the nervous system[5], protects 
neurons from oxidative stress by reinstating glutathione levels 
decreased by glutamate and hydrogen peroxide[17,18]. It also protects 
cardiac muscle from ischemia/reperfusion (I/R) injury by preserving 
mitochondrial function[19]. It acts on the cardiovascular system by 
promoting angiogenesis and exerting a key role in 
cardioprotection[20,21]. Eventually, H2S is involved in the modulation 
of sepsis processes, where it is thought of exerting protective effects 
by mainly decreasing inflammation[22], and it is implicated in a 
variety of inflammatory[23] and vascular disorders[24]. 
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1.2. Biosynthesis 
 
H2S is a colorless gas with a strong odor of rotten eggs. Oxidation of 
H2S yields elemental sulfur, sulfur oxide (SO2), and sulfates such as 
sulfuric acid.  
In aqueous solution, H2S is a weak acid and it can be dissociated to 
hydrosulfide and sulfide ions in the following sequential reactions: 
 
H2S⇄ H+ + HS- ⇄ 2H+ + S2- 
 
Even in an aqueous solution, about one third of H2S remains 
undissociated at pH 7.4 as theoretically predicted by Henderson-
Hasselbach equation. Indeed, with a pKa1 ~7.0 and a pKa2 >17, there 
is essentially no S2- in biological tissues, nearly equal amounts of H2S 
and HS- within the cell, and approximately a 20% H2S/80% HS- ratio 
in extracellular fluid and plasma at 37°C and pH 7.4. Due to the 
temperature sensitivity of pKa1, the H2S/HS- ratio remains nearly 
constant in blood and tissues of ectothermic vertebrates over a wide 
range of body temperatures. Given its lipophilicity, H2S freely 
permeates plasma membranes and penetrates all types of cells; this 
skill gives to H2S a high biological potential[25]. 
 
1.3. Endogenous generation and metabolism of 
H2S 
 
Production of H2S in mammalian tissues has been known for a long 
time, but it was viewed as a metabolic waste. Aside from circulating 
H2S, a significant amount of H2S is produced in various tissues. 
Significant H2S levels were detected in mammalian tissues from 
human, rat, and cow in the range of 50-160 µM[3,4].  
Endogenous H2S can be generated by both enzymatic and non-
enzymatic pathways. A minor endogenous source of H2S is the non-
enzymatic reduction of elemental sulfur to H2S using reducing 
equivalents obtained from the oxidation of glucose, which has been 
described in erythrocytes[1]. Human erythrocytes produce H2S when 
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provided with elemental sulfur or inorganic polysulfides[26]. 
Increased oxidative stress and hyperglycemia will promote H2S 
production from this path. All essential components of this non-
enzymatic path are present in vivo, including the supply of reducible 
sulfur. The presence of μM concentration of sulfur in blood 
circulation has been reported in humans or mice. Sulfide, via non-
enzymatic oxidation, yields thiosulfate. The latter can be converted 
to sulfite by thiosulfate reductase in liver, kidney, or brain tissues or 
by thiosulfate sulfurtransferase in the liver.  
The enzymatic pathway involves mainly two enzymes, cystathionine 
β-synthase (CBS) and cystathionine γ-lyase (CSE), which are 
expressed in many tissues with a heterogeneous distribution [27]. 
(Fig. 2) 
 
 
 
Fig 2. Structures of three key H2S-generating enzymes. A: structure of human CBS; 
B: structure of human CSE; C: structure of human 3MST 
 
Both enzymes produce H2S from the condensation of L-cysteine and 
other thiols, such as L-homocysteine [5,28,29] and use pyridoxal-5’-
phosphate as a cofactor which are deputed to the production of H2S 
from L-Cysteine. Specifically, CBS is predominant in the central 
nervous system (CNS)[30], while CSE is expressed in the thoracic 
aorta and has been thought to be the major H2S-producing enzyme in 
the vascular system and in many other districts[28]. 
Another route that leads to H2S production involves the participation 
of the enzyme cysteine aminotransferase (CAT), which catalyzes a 
reaction between L-cysteine and α-ketoglutarate, leading to the 
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formation of 3-mercaptopyruvate and L-glutamate. 3-
mercaptopyruvate sulfurtransferase (3MST) (Fig. 2) can produce 
H2S from 3-mercaptopyruvate by desulfuration[31,32]. As the end 
product of CBS- and CSE-catalyzed cysteine metabolism, H2S exerts a 
negative feedback effect on the activity of these enzymes[20,33] (Fig. 
3). Both CSE and CBS are localized in the cytoplasm, while 3MST is 
mainly localized into mitochondria and partly in cytoplasm. 
 
Fig. 3. Biosynthesis and transformation of H2S in mammalian cells. 
 
1.4. Catabolism 
 
H2S is a reducing species which can be easily consumed by a variety 
of circulating oxidant agents[15,16]. In vivo H2S is metabolized rapidly 
by a multitude of different chemical and enzymatic processes. Of 
these, the mitochondrial oxidation mechanism represent the most 
important route of H2S catabolism. It involves several enzymatic 
steps catalyzed by quinine oxidoreductase, S-dioxygenase and S-
transferase and, overall, leads to the formation of thiosulfate. 
Subsequently, thiosulfate is converted to sulfite by rhodanase and 
finally the major stable product, sulfate, by sulfite oxidase[34,35]. In 
contrast, cytosolic methylation of H2S by thiol-S-methyltransferase to 
yield methanethiol and dimethylsulfide represent another less 
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important mechanism of H2S degradation, and therefore accounts for 
a smaller amount of H2S. Additionally, H2S can be scavenged by 
methaemoglobin to form sulfhaemoglobin or consumed by metallo- 
or disulfide-containing molecules such as oxidized glutathione[36]. It 
can also be oxidized by activated neutrophils to form sulfite[37]. As a 
reducing agent, it acts as scavenger of reactive oxygen species such 
as peroxynitrite[15], hypochlorite[16], superoxide[37] or hydrogen 
peroxide[38] (Fig. 4). 
 
 
Fig 4. H2S catabolism 
 
1.5. Non-specific target of H2S 
 
Over the years, various studies have indicated the role of H2S in 
many processes. This endogenous mediator exerts physiological 
activities at concentrations lower than 20µM, where it can be a 
substrate, able to donate electrons to the electron transport chain at 
the level of ubiquinone[34], enhancing the final ATP biosynthesis (Fig. 
5). 
Electrons go through the respiratory chain, passing to complex III, 
cytochrome oxidase and finally to oxygen. The oxidation of sulfide is 
catalyzed by the sulfide-quino-oxidoreductase, an enzyme present in 
the inner mitochondrial membrane. Thus, at low concentration this 
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gaseous mediator can stimulate oxidative phosphorylation and 
ultimately increase ATP biosynthesis. 
In contrast, at higher concentration (about 50 µM) H2S affects the 
activity of the respiratory chain, causing a non-competitive complete 
inhibition of the complex IV, the cytochrome oxidase[39,40]. 
 
 
Fig.5. Effects of H2S due to non-specific target. Activity on the mitochondrial 
respiratory chain. 
 
In line with the well-known chemical behavior of inorganic and 
organic sulfites, the first mechanistic explanation of the biological 
activity of H2S was ascribed to interaction with redox systems. 
Indeed, H2S reacts with at least four different reactive species: 
superoxide radical anion[37],  hydrogen peroxide[38], peroxynitrite[15] 
and hypochlorite[16]. These compounds are highly reactive and their 
neutralization by H2S results in the protection of proteins and lipids 
from damage induced by such aggressive molecules[15,16]. A non-
specific cytoprotective role for H2S has been found to result also in 
9 
 
the suppression of ROS production, reduction of upregulated cleaved 
caspase-3 expression, prevention of reduced glutathione (GSH) fall, 
and mitochondria membrane potential loss in rat 
cardiomyoblasts[41]. Moreover, H2S can reduce some relevant events 
associated with oxidative and proteolytic stresses, such as nitration 
of tyrosine residues and myocardial matrix metalloproteinases 
activation[42]. H2S protects from oxidative stress by increasing the 
production of GSH, by enhancing cystine/cysteine transporters, and 
redistributing GSH to mitochondria[17]. All these findings, however, 
cannot allow a full and exhaustive explanation accounting for all the 
antioxidant effects exhibited by H2S, and further investigations are 
still needed. 
 
1.6. Specific target of H2S 
 
Among the above non-specific activities of H2S, there are many other 
effects due to the interaction with specific molecular targets and 
proteins. In particular, in many systems its action is mediated by the 
activation of ion channels.  
Ion channels are pore-forming membrane proteins that help 
establish and control the small voltage gradient across plasma 
membrane of cell or intracellular organelle membranes. The driving 
forces for the ion flows are the membrane potential and the ionic 
gradients for specific ions like Na+, K+, Ca2+, and Cl-, which allow for 
the flow of ions down their electrochemical gradient. These channels, 
individually or collectively, participate in the regulation of cell 
differentiation, muscle contractility, neurotransmitter release, and 
hormone secretion. 
 
1.6.1. KATP channels 
 
One of the most known and well described mechanism of action of 
H2S is that involving the ATP-sensitive potassium channels (KATP)[43]. 
KATP channels are almost ubiquitous and their role is particularly 
important in the regulation of biological functions in several 
tissues/systems. By targeting KATP channels, H2S regulates a plethora 
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of activities by exerting beneficial protective effects against I/R 
damage, hypertension, nociception, apoptosis and inflammation.  
Extensive experiments on vascular tissue strongly suggest that H2S-
induced vasorelaxation is mainly caused by KATP channel opening, 
largely confirmed by the ability of glibenclamide, a KATP channel 
antagonist, to reduce the vasorelaxant effects of H2S[43,44]. 
Electrophysiological studies provide direct evidence that exogenous 
H2S increases macroscopic or unitary KATP currents. In fact, H2S-
induced hyperpolarization of the cell membrane is partially 
abolished by glibenclamide. 
The KATP channel exhibits a hetero-octameric architecture. It is 
composed of the combination of two kinds of transmembrane 
subunits: a pore-forming protein, belonging to the family of inward 
rectifying potassium channels (Kir); and regulatory proteins, known 
as SUR (sulphonylurea receptor) subunits, which are members of 
ATP-binding cassette proteins and can be viewed as sensors of 
ATP/ADP ratio. In particular, KATP channels are formed by four Kir 
proteins belonging to the subfamily 6 (Kir6), and each of them is 
associated with a SUR subunit[45,46]. 
Two subtypes of Kir6 proteins (classified as Kir6.1 and Kir6.2) and 
three subtypes of SUR (SUR1 and the splicing variants SUR2A and 
SUR2B) are known to be involved in the structure of KATP 
channels[47].  
Different tissues express KATP channels formed by different 
combinations of Kir6-SUR subunits (Table 1). Typically, the 
pancreatic channels are composed of the combination of Kir6.2 and 
SUR1; cardiac channels result from the association of Kir6.2 and  
SUR2A; vascular smooth muscle (VSM) expresses KATP channels 
formed by Kir6.1 and SUR2B, while non-VSM channels are a 
combination of Kir6.2 and SUR2B. 
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SUR Isoform Kir Isoform Tissue expression 
SUR1 Kir6.1 Basal Ganglia 
SUR2B Kir6.1 Aorta 
SUR1 Kir6.2 Pancreas 
Hypothalamus 
Cardiac Muscle (atria) 
SUR2A Kir6.2 Skeletal Muscle 
Cardiac Muscle (atria and 
ventricles) 
SUR2B Kir6.2 Non-VSM 
(bladder, stomach, colon) 
SUR1 
SUR2B 
SUR1 +2B 
Kir6.2 Substantia Nigra 
SUR2B Kir6.1 
Kir6.2 
VSM 
 
Table 1. Common combinations of KATP channel subunits observed in various 
Tissues. 
 
Direct interactions of H2S with this kind of potassium channel type, 
possibly due to S-sulfhydration of specific cysteine residues, has 
been described by Jiang et al.[48], who showed that H2S interacted 
with specific cysteine residues (Cys6 and Cys26) located on 
extracellular loop of SUR subunit of KATP channel complex. H2S 
induces covalent modification of cysteine residue by transferring its 
sulfhydryl group to cysteine residue of the concerned protein. S-
sulfhydration usually enhances the activity of the modified proteins. 
H2S-induced neuroprotection and suppression of glutamate toxicity 
was partially mediated by the activation of KATP channels as well as 
the cardioprotective effects. 
The cardioprotective effect of H2S involves not only the opening of 
KATP channels, but also the activation of cardiac ERK (Extracellular 
Signal Regulated Kinases) and/or Akt pathways in addition to 
preserving mitochondrial structure and function[19,49].  
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1.6.2. KCa channels 
 
Besides the KATP, other types of potassium channels are stimulated 
by H2S. In particular, a possible target for H2S action in several 
systems is the calcium-activated potassium channels (KCa). 
There are three different subtypes of KCa, which are classified in 
accordance with single channel conductances as SK (small 
conductance, 2-25 pS), IK (intermediate conductance, 25-100 pS), 
and BK (big conductance, 100-300 pS). Of them, the BK is the most 
investigated and promising one, thanks to the influence exerted on 
membrane potential due to its high conductance. In fact BK channels 
possess a unique property of a double mechanism of activation: they 
are regulated by intracellular calcium concentration and membrane 
potential, both acting in an independent but synergistic manner[50]. 
Together with the principal voltage- and calcium-dependent 
activation mechanisms, other stimuli are known to contribute to BK 
channel activation. BK channels have an important biological role, 
because they are involved in a plethora of physiological functions, 
such as the control of vascular tone[51], hormone secretion[52,53], 
release of neurotransmitters and electrical activity of cells[54,55]. 
Moreover, H2S activates both the SK and the IK channels in the 
vascular endothelium of rat mesenteric arteries[56]. In contrast, 
conflicting data exist concerning the effects of H2S on the BK 
channels. In fact, while H2S inhibits BK heterogously expressed in 
HEK-293 cells[57] and constitutively expressed in rodent carotid 
body[58], it activates BK channels expressed in the GH3 pituitary 
tumour cell line[59]. 
A recent study focused on the involvement of H2S in the regulation of 
the activity of BK channels in the vascular tone has been 
demonstrated by using paxilline and iberiotoxin, two blockers of BK 
potassium channels. They both failed to antagonize the effects of the 
sodium salt of H2S, sodium hydrosulfide (NaHS), in VSM cells, 
indicating that the activation of this important class of potassium 
channels does not play a significant role in the H2S-mediated 
vasorelaxation[60]. 
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1.6.3. Kv7 channels 
 
Kv7, voltage-gated potassium channels, play a crucial role in 
stabilizing the membrane potential at negative resting values, 
thereby counteracting electrical excitability in several cell types[61]. 
Presently, five Kv7 subtypes are recognized (Kv7.1–Kv7.5), each 
showing a distinct tissue distribution[62] (Fig. 6). 
 
 
 
Fig 6. Tissue distribution of Kv7 channels. The different panels in the figure report 
the principal sites of expression for each Kv7 channel subunit. In addition to those 
shown, it should be noted that Kv7.1 subunit expression has been detected in 
epithelial cells from various tissues not shown in the figure (lungs, pancreas, liver, 
thymus, kidneys, adrenal glands, and testis)[62]. 
 
The presence of Kv7 channels has been recently demonstrated in 
VSM cells[63] where their activation keeps the resting membrane 
voltage far from the threshold for activation of voltage-sensitive Ca++ 
channel (about -40 mV), thus preventing vasoconstriction[64]. 
Vascular Kv7 channels, and in particular those incorporating Kv7.4 
subunits are presently viewed as key elements in the regulation of 
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blood vessel contractility[65]. By using NaHS to induce vasorelaxation 
in rat aortic rings, the effect was antagonized by 
tetraethylammonium (TEA), a non-specific blocker of Kv channels. 
The Kv7-blockers linopirdine and XE-991 markedly antagonized the 
vasodilator responses to NaHS, adding further support to the 
involvement of Kv7 potassium channels and suggesting that the 
activation of Kv7 channels contributes to the vasorelaxing responses 
evoked by H2S[60].  
To provide direct evidence for the ability of H2S to activate currents 
mediated by Kv7 channels, the effects of NaHS were evaluated with 
retigabine, a Kv7-activator. The result was an irreversible response, 
possibly suggesting that H2S covalently modified Kv7.4 channels and 
that the functional changes were additive to those of retigabine, 
indicating potential different binding sites[60]. Such an hypothesis 
might also explain the difference in efficacy between retigabine and 
NaHS. Kv7 channels (particularly the Kv7.4 subtype), are important 
pharmacological targets for H2S, and that the direct activation of this 
class of ion channels mediates a significant part of the vasorelaxing 
effects of this gaseous transmitter.  
 
1.7. Biological role of H2S  
 
Presently, an exhaustive knowledge of the biological effects of the 
gasotransmitter H2S is not yet available. This pleiotropic gas is able 
to exert numerous beneficial effects in human body when present at 
physiological concentrations, by interacting with signaling proteins. 
The major roles are reported to be played in many systems such as 
the cardiovascular, respiratory, gastrointestinal, endocrine and 
central nervous systems. 
This huge array of effects in many organs include non-specific 
cytoprotective roles (i.e., suppression of ROS production) and 
specific mechanisms of action (i.e., by specific molecular targets). For 
instance, H2S has been shown to act as a modulator of N-methyl-D-
aspartate receptor currents and hippocampal long-term 
potentiation. It also open adenosine triphosphate-dependent K+ 
(KATP) channel and interacts with vasoactive gaseous mediators to 
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relax smooth muscle[33,43,66]. It protects cardiac muscle from I/R 
injury by preserving mitochondrial function[19]. It acts on 
cardiovascular system by promoting angiogenesis and exerting a key 
role in cardioprotection [20,21].  
 
Cardiovascular system. 
In the cardiovascular system H2S is now considered, together with 
NO, a critical contributor to the regulation of homeostasis. H2S also 
evokes relaxing responses in VSM, and this action has been observed 
in large vessels, such as rat thoracic aorta and portal vein[28], as well 
as (and with higher potency) in peripheral resistance vessels, where 
it plays a more significant role in the regulation of vascular 
resistance and blood pressure[44]. The vasorelaxant effects of H2S are 
mainly, but not exclusively, due by opening the KATP channels in VSM 
cells. In fact, in addition to KATP channels, Kv7 channels (particularly 
the Kv7.4 subtype), mediate a significant part of the vasorelaxing 
effects of this gaseous transmitter[60]. Together with its vasorelaxing 
activity, H2S (such as NO) is endowed with a wide range of additional 
biological roles, which are relevant for a polyedric control of the 
cardiovascular system. 
In the heart, H2S cause negative inotropic and chronotropic effects by 
activating plasma membrane (sarcKATP) and mitochondrial 
(mitoKATP) channels and inhibiting L-type Ca++ channel activity, and 
it exerts protection from I/R cardiac injury. In fact, the opening of 
KATP channels in myocardium has been viewed as playing a pivotal 
role in cardioprotection during irreversible I/R injury, which is 
specifically observed in cardiac ischemic preconditioning[67]. 
The key role in the negative regulation of chronotropism and 
inotropism in the myocardium has been demonstrated with the use 
of the sodium salt form of the gaseous compound. In fact, when it is 
exogenously administrated as NaHS (50-200 µM), it showed a 
decreased velocity of diastolic depolarization and rate of pacemaker 
firing in normal pacemaker cells; these effects were inhibited by 
glibenclamide (20 µM), a classical KATP channel blocker, suggesting 
that the opening of KATP channels likely underlies the effect of H2S[68].  
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Reperfusion of the isolated Langendorff-perfused heart with NaHS 
after ischemia attenuated arrhythmias and improved cardiac 
function during I/R[69]. 
At present, it is widely recognized that the myocardium subjected to 
episodes of sublethal ischemia becomes less sensitive to subsequent 
more severe ischemic insults. This phenomenon is known as 
‘‘ischemic preconditioning’’ (IPC), and such a protective effect 
against myocardial I/R injury is mostly due to activation of the 
cardiac KATP channels, particularly those expressed in the 
mitochondrial inner membrane[70]. Endogenous H2S is likely to play a 
role as a mediator of IPC and, consistently, protective effects of 
exogenous H2S against myocardial I/R injury (i.e. pharmacological 
preconditioning) have been shown both in isolated perfused rat 
heart and experimental models of acute infarct. These anti-ischemic 
effects are abolished by KATP channel blockers. This is consistent with 
the negative inotropic effects of other KATP channel activators, which 
induce cell membrane hyperpolarization. NaHS-induced cardiac 
protection effect was also suppressed by 5-hydroxydecanoate (5-
HD)[71]. 5-HD is a selective mitoKATP channel blocker while 
glibenclamide blocks the plasma membrane KATP channels. KATP 
activation can result in the closing of L-type calcium channels, 
reducing calcium entry, and inhibiting muscle contractility[72]. 
Notably, all the beneficial cardioprotective actions of H2S are due to 
low concentrations, because recent clinical reports highlight that H2S 
poisoning causes cardiac injury due not only to local hypoxemia of 
the heart, but also to selective organ toxicity of the myocardium[73]. 
The physiological concentration of H2S in plasma or in tissue is finely 
regulated by the rate of generation and consumption. Significant 
changes from physiological levels contribute to various diseases. 
Consistently, significant changes of H2S-producing enzyme 
expression/activity have been associated with several pathological 
states. 
 
Respiratory system. 
H2S seems to play significant beneficial roles in the airways, which 
have been described in recent studies. In addition to H2S-induced 
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vasorelaxation, the effect of H2S has been investigated also in rings of 
bronchial smooth muscle of two rodent species, where it elicits 
strong relaxation in isolated bronchus rings from the mouse, but 
produces only slight relaxation in guinea pig rings. Although KATP 
channel activation and the possible cooperation of the NO-cGMP 
pathway are clearly involved in the modulation of vascular tone[33,74], 
the H2S-evoked relaxation of the mouse bronchial smooth muscle 
does not involve these two pathways[75]. 
H2S content and CSE activity are significantly related and they both 
enhanced in isolated rat lung submitted to I/R injury Moreover, their 
relevant relation is also shown in hypoxic polmonary hypertension, 
where there is an decrease of the H2S production due to the 
suppression of  both gene expression and activity of CSE. The 
exogenous administration of H2S restored the basal levels[76] and 
pulmonary vascular inflammation was reduced[77]. Reduced amounts 
of endogenous H2S are also involved in the development of 
pulmonary artery collagen remodeling, induced by high pulmonary 
blood flow. In fact, H2S, through the inhibition of the production of 
some vasoactive peptides, such as endothelin-1 and connective 
tissue growth factor, ensures the control of extracellular matrix 
collagen metabolism (ECM)[78]. These effects are unlikely to be 
related to KATP channel opening, but they are probably linked to a 
decreased extracellular signal-regulated kinase (ERK1/2) 
phosphorylation[79].  
The CSE/H2S pathway seems to exert beneficial roles also in the two 
most important obstructive airway diseases: asthma and chronic 
obstructive pulmonary disease (COPD). In an ovalbumin-induced 
asthmatic rat model and in human asthmatic patients, levels of 
endogenous H2S decrease with the progression of disease 
severity[80,81]. Consistently, increased levels of serum H2S in milder 
COPD may play a useful role in airway protection, antagonizing 
oxidative stress and airway inflammation and preventing the 
progress of COPD. Accordingly, when H2S levels fall significantly, 
patients show an acute exacerbation of COPD[82]. 
The antiinflammatory and antioxidant effects of H2S account also for 
its beneficial action in acute lung injury, where H2S reduces protein 
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oxidation, 3-nitrotyrosine formation, and attenuates the tissue 
concentration of proinflammatory cytokine, such as interleukin 
(IL)1-β, and determines an upregulation of antiinflammatory 
cytokines, such as IL-10[83].  
 
Gastrointestinal System. 
After the recognition of CSE and CBS in rat gut, H2S became to be 
viewed as a possible important mediator of gastrointestinal motility. 
The administration of exogenous H2S causes dose-dependent 
relaxation of the ileum and colon smooth muscle[84-86], this effect is 
fully antagonized by glibenclamide indicating the involvement of 
KATP channels. Together with its relaxant effects, it is noteworthy that 
H2S can exert antinociceptive effects, as demonstrated by a H2S-
mediated reduction of pain induced by colorectal distension in both 
healthy rats and those with colitis. Again, these effects were 
prevented by KATP-blockers, but they were independent of the 
relaxant activity of H2S on smooth muscle[84,86].  
Both CSE and CBS have been found in the gastric mucosa, thus in the 
gastric system, H2S plays a significant role as a protective factor 
against mucosal injury.  
 
Endocrine System. 
KATP channels elicit a crucial role in controlling insulin secretion from 
pancreatic β-cells. The hypoglycemic responses induced by KATP-
blockers (i.e. glibenclamide) are usefully employed in the 
pharmacological management of type 2 diabetes. H2S is likely to be 
involved in controlling insulin secretion, because relatively large 
amounts of both CSE and CBS have been found in the pancreas. In a 
recent study, pancreatic CSE expression and H2S production were 
found to be correlated and their levels were greater in diabetic rats. 
It has been recently shown that high glucose increases CSE 
expression and H2S formation in β-cells from normoglycemic 
animals. Exogenous H2S inhibits high glucose-induced apoptosis of β-
cells; thus, a glucose-induced enhanced production of endogenous 
H2S can be viewed as a protective mechanism which preserves β-
cells from glucotoxicity and attenuates the apoptotic death of 
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pancreatic β-cells[87]. Another research group[88] reported that the 
enzymatic biosynthesis of H2S is impaired in a mouse model of type 1 
diabetes, and that such a reduction of H2S bioavailability is 
associated with an alteration of vascular reactivity. Given the close 
correlation between diabetes and its cardiovascular complications 
and the pivotal regulatory roles played by H2S in the cardiovascular 
system, a deficit of H2S can be a relevant pathogenic step in the 
progression of diabetes-associated cardiovascular diseases. 
 
Central Nervous System. 
As an almost ubiquitous bioactive molecule, H2S exerts important 
regulatory effects in several biological systems. For instance, it is 
pivotally involved in the control of important functions in the CNS. A 
high expression of CBS in the rat hippocampus and cerebellum was 
first observed by Abe and Kimura in 1996, who also proved the 
production of H2S in brain homogenates[5]. These early findings were 
strengthened by the evidence that CBS inhibitors reduced H2S 
concentrations in the brain; further, brain levels of H2S were also 
reduced in CBS-deficient mice[89]. In CNS neurons, H2S enhances 
cAMP production, thus leading to an increased sensitivity of N-
methyl-D-aspartate receptors to glutamate[90].  
The antiinflammatory and neuroprotective effects of  endogenous 
H2S biosynthesized by CBS in human astrocytes have been recently 
reported. These results suggest a great therapeutic potential for 
exogenous sources of H2S in widely diffused neurodegenerative 
pathologies, such as Parkinson’s and Alzheimer’s disease[91].  
Altered expression of CBS and endogenous H2S in vivo leads to many 
neurodegenerative diseases, and replenishment with exogenous H2S 
reversed the pathology. Similarly, altered expression of CSE and 
endogenous H2S levels were shown to be responsible for 
inflammation[92], atheroscleorosis[93], diabetes[94], asthma[80] and 
important cardiovascular disorders, such as hypertension[95]. 
 
Lastly, H2S is involved in the modulation of sepsis processes, where it 
is suspected of exerting protective effects by mainly decreasing 
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inflammation[22], and is implicated in a variety of inflammatory[23] 
and vascular disorders[24]. 
 
1.8. Role of H2S in inflammation: anti- and pro-
inflammatory activity 
 
The role of H2S in inflammatory processes is certainly particularly 
complicated since H2S has been reported to exert both pro-
inflammatory[79,96-98] and anti-inflammatory effects[49,83,92,99]. The 
controversial views on the role of H2S in inflammation cannot be 
readily explained by the amounts of H2S generated or the 
inflammation models tested. Moreover, many other factors influence 
the role of H2S in inflammation including animal species (rats vs. 
mice and others), inflammation models (regional vs. systemic 
inflammation), and the organ origin of H2S (brain vs. pancreas, etc.). 
The precise mechanism of action by which H2S acts as an 
inflammatory mediator is however not yet clear, despite wide 
attempts to better understand its implication in this process. 
Moreover, the activity of endogenous H2S compared with exogenous 
H2S should be carefully evaluated. Most studies to date have used 
exogenously applied H2S donors to show the role of H2S in 
inflammation. This approach may be useful in determining the 
therapeutic value of H2S in inflammation but would not substantiate 
the role of endogenous H2S in the process. 
One of the earliest proposed benefits of H2S as a physiological 
modulator in the vasculature is its ability to prevent 
inflammation[6,84,92]. 
It has been known long ago that H2S possessed an anti-proliferative 
effect on T lymphocytes[100] and that these effects would limit the 
development of inflammation. 
A key event in inflammation is the recruitment of circulating 
leukocytes into damaged tissue. Andruski et al.[101] demonstrated 
that exogenous administration of H2S-donors limited leukocyte 
recruitment and trafficking and that inhibitors of H2S synthesis 
increase them[92]. These anti-inflammatory effects of H2S were 
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mediated via the KATP channel because responses could be blocked 
by glibenclamide treatment. 
Moreover, the protective anti-inflammatory action of H2S is also 
realized by the upregulation of anti-inflammatory and cytoprotective 
genes. Indeed, H2S promotes the translocation of the nuclear 
transcription factor Nrf2 from the cytosol to the nucleus resulting in 
the subsequent expression of numerous detoxifying genes such as 
heme oxygenase 1 (HO-1), superoxide dismutase, and 
catalase[102,103]. 
Again, in the contest of inflammatory events, decreased tissue IL-1β 
levels, increased IL-10 levels and attenuated protein oxidation were 
all observed after H2S-donor administration[83].  
Increased GSH level and decreased ROS generation in the presence of 
NaHS were associated with reduced secretions of IL-1β, IL-6, and IL-
8[17]. 
Administration of H2S also prevented many of the “pro-
inflammatory” effects of non-steroidal anti-inflammatory drugs 
(NSAIDs), including the elevation of intracellular adhesion molecule 
(ICAM)-1 and lymphocyte function associated antigen-1 (LFA-1) 
expression and the increased expression of mucosal tumor necrosis 
factor α (TNF-α)[104]. 
In the CNS, neuroinflammation is a point for elucidating the role of 
H2S in inflammatory process. The activation of glial cells and release 
of inflammatory factors in the brain, together with the recruitment of 
peripheral immune cells, jointly result in neuroinflammatory 
damage. This will likely lead lead to neurodegenerative diseases, 
such as Alzheimer’s disease and Parkinson’s disease[91]. 
Exogenously administered H2S acts on sensitive neurons and 
promotes the opening of KATP channels and subsequent 
antinociception[105]. Thus, H2S acts as a negative regulator of visceral 
nociception by activating KATP channels and attenuating pain. 
Yet, experimental evidence shows that H2S behaves as a pro-
inflammatory factor in various animal models, including hindpaw 
edema[106], acute pancreatitis[107], LPS-induced endotoxemia[98], and 
cecal ligation and puncture induced sepsis[79]. 
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The aforementioned studies suggest that increased endogenous H2S 
could be harmful to inflammed tissues and organs. If this is the case, 
inhibiting the activity of H2S generating enzymes would be 
beneficiary. To support this view, Collin et al.[97] showed that 
pretreating animals with the inhibitor of H2S synthesis, 
propargylglycine (PAG), markedly inhibited LPS-induced rise in lung 
and liver myeloperoxidase activity and ameliorated lung and liver 
tissue damage. PAG treatment also blunted the increase in the pro-
inflammatory cytokine and chemokine levels, and abolished 
leukocyte activation and trafficking in LPS-induced endotoxemia. In 
cecal ligation and puncture induced sepsis, PAG treatment 
attenuated inflammatory response by reducing neutrophil 
infiltration and reducing animal mortality. One mechanism of these 
pro-inflammatory effects is that H2S stimulates sensory nerve 
endings, releasing endogenous tachykinins such as substance P, 
calcitonin gene-related peptide, and neurokinin A, thereby 
contributing to neurogenic inflammation. More than two decades 
ago, studies in the rat showed the activation of sensory nerves after 
inhalation of toxic concentration of H2S [108]. 
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1.9. Importance of using H2S-donors 
 
The concentration of H2S in plasma or in tissue is finely regulated by 
the rate of generation and consumption. Consistently, significant 
changes in H2S-producing enzyme expression/activity have been 
associated with several pathological states. In particular, the 
consequences of an altereted expression/activity of the H2S-
generating enzymes can be observed in the cardiovascular system, 
where its impaired production lead to hypertension[95]. 
In addition, this unbalanced production is also related to 
inflammatory events. Nevertheless, the fluctuation of endogenous 
H2S level is an impossible parameter to measure, because of a wide 
number of factors, thus it is extremely hard to determine whether 
H2S behaves as anti-inflammatory or pro-inflammatory agent.  
Various different hypothesis have been presented regarding the role 
of H2S in inflammation. Essentially, anti-inflammatory activity is 
elicited only when low concentrations of the gas are present in 
biological fluids, whereas higher concentration evoked pro-
inflammatory effects. 
For many reason dealing with this gas is complicated. Therefore, its 
pharmacological modulation is becoming a challenging field of 
research in drug discovery[109,110]. Furthermore, the route of 
administration of H2S may also influence the outcomes. Even at the 
same concentration, H2S may cause opposite effects depending on its 
releasing rate. 
Since the administration of gaseous H2S is limited by the risk of 
overdose, the use of appropriate chemicals, behaving as H2S-
releasing agents, appears to be safer and largely preferred. 
To date, H2S-releasing “drugs” used in biological experiments have 
been largely restricted to simple sulfide salts, most commonly NaHS.  
This salt is the prototypical H2S-generating agent. It releases H2S 
instantaneously in aqueous solution. 
Calcium sulfide (CaS) has been proposed as a possible 
alternative[111], but it should be noted that the rate and mechanism of 
H2S release from these two inorganic salts are almost equivalent. The 
release of endogenous H2S from cells is likely to occur in lesser 
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amounts and at a much slower rate than that from sulfide salts. 
Therefore sulfide salts do not mimic the biological effects of 
naturally produced H2S[112] and are not appropriate for clinical uses 
since the quick release of H2S may cause adverse effects, such as 
rapid and excessive lowering of blood pressure. 
Accordingly, ideal H2S-releasing drugs for therapeutic purposes 
should generate H2S at slow rates in order to correctly mimic the 
biological effects of endogenous H2S[109]. 
Among these compounds, the phosphinodithioate derivative 
GYY4137 (morpholin-4-ium-4-methoxyphenyl-morpholino-
phosphinodithioate) (Fig. 7) is currently used for pharmacological 
studies, since it ensures a sustained release of H2S over a prolonged 
period[112]. GYY4137 is a water-soluble molecule and it was one of a 
series of compounds synthesized  on the basis of the structure of 
Lawesson’s compound, which releases H2S in organic solvents. 
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Fig. 7. Chemical structure of GYY4137 
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1.10. H2S-donors: natural and synthetic origin  
 
The search for organic molecules capable of releasing H2S over 
extended periods of time is considered an innovative strategy in 
drug discovery. Such molecules might represent potential 
pharmacotherapeutic tools for a wide array of diseases.  
In this thesis, the potential release of H2S from both natural and 
synthetic compounds has been evaluated. 
  
Thioamides 
Recently, interesting H2S-releasing agents have been discovered in 
aminothiol[113] and aryl thioamide[114] derivatives. Also, the H2S-
donor properties of dithiolethiones and thioamides have been widely 
used for the synthesis of multitarget drugs[115-117]. A small library of 
arylthioamides, easily prepared through proper synthetic routes, has 
been reported[118]. Among the wide array of compounds, which differ 
for chemical substituent moieties, p-hydroxybenzothioamide (Fig. 
8), named IS-176,  was selected as the lead compound of the series. 
 
S
NH2
HO  
 
Fig. 8. Chemical structure of p-hydroxybenzothioamide, IS-176. 
 
Polysulfides 
The above mentioned pharmacokinetic profiles are also exhibited by 
some natural derivatives: organic polysulfide derivatives of garlic, 
belonging to the botanical family of Alliaceae, are natural sources of 
H2S. 
Recent and convincing evidence shows that some organic 
polysulfides of garlic, such as diallyl disulfide (DADS), act as H2S-
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releasing compounds with relatively slow mechanism, requiring the 
presence of GSH[26].  
Garlic is rich in organosulfur compounds considered responsible for 
most of its pharmacological activities. Allicin (diallyl thiosulfinate), 
the main organosulfur compound, is produced from the amino acid 
alliin by action of the enzyme alliinase when garlic is crushed. Allicin, 
unstable in aqueous solution, rapidly decomposes mainly to diallyl 
sulfide (DAS), DADS, diallyl trisulfide (DATS), and ajoene[119] (Fig. 9). 
After consumption, neither allicin nor its metabolites have been 
found in blood or urine[120], indicating that these compounds are 
rapidly metabolized. 
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Fig. 9. Chemical structure of  diallyl monosulfide (DAS), diallyl disulfide (DADS) 
and diallyl trisulfide (DATS). 
 
H2S production from organic polysulfides is facilitated by allyl 
substituents and by increasing numbers of tethering sulfur atoms. 
DADS (but also DATS), by interacting with the endogenous thiol GSH 
by a typical thiol/disulfide exchange, undergoes nucleophilic 
substitution at the α carbon of the allyl substituent. Nevertheless, 
this reaction does not lead to the direct production of H2S, but it 
yields S-allylglutathione[121] and allyl perthiol[122,123], a key  
intermediate in the H2S production (Fig. 10, reaction A). In fact, the 
resulting allyl perthiol can be submitted to different chemical routes. 
In turn, it undergoes nucleophilic substitution at the S-atom yielding 
allyl-GSSG and H2S. The allyl-glutathione disulfide is an additional 
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target for nucleophilic substitution at the α carbon, leading to further 
H2S production.  
The allyl perthiol may also undergo nucleophilic substitution at the α 
carbon yielding S-allylglutathione and H2S2 that in turn reacts with 
GSH to produce H2S (Fig. 10, reactions B and C). Organic disulfides 
substituted with only one allyl group may also produce H2S, albeit in 
lower yields.  
Protein thiols and other biological thiols may compete with GSH for 
organosulfur compounds in certain microenvironments such as 
plasma membranes, resulting in H2S formation as well as protein 
covalent modifications. 
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Fig. 10. Mechanism of H2S release from diallyl disulfide. 
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Therefore, organic polysulfide derivatives of garlic are viewed as 
useful templates for drug discovery and innovative 
pharmacotherapeutic agents.  
 
Isothiocyanates 
Beyond the natural organic polysulfides, other important molecules 
belonging to the Brassicaceae family, are enormously recognized for 
their beneficial effects. 
Plants that belongs to this order tipically contain glucosinolates, 
which are sulfur-containing secondary plant metabolites. The 
general structure comprises β-D-thioglucose group, a side chain (R) 
and a sulphonate oxim moiety. 
The first glucosinolates were discovered in the early 19th century: 
the widely distributed prop-2-enyl glucosinolate (sinigrin, Fig. 11b) 
was isolated from black mustard (Brassica nigra) seed and 4-
hydroxybenzyl glucosinolate (sinalbin, Fig. 11a) from white mustard 
(Sinapis alba) seeds. 
X-ray crystallographic studies showed the C=N bond to have an anti 
(Z) configuration[124]. Therefore, glucosinolates are also called β-D-
thioglucoside-N-hydroxysulfates, (Z)-N-hydroximinosulfate esters, 
or S-glucopyranosylthio hydroximates. The side chain R is 
structurally multifaceted and a variety of glucosinolates have been 
described so far[125]. 
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a)  
b)  
 
Fig 11. Chemical structure of sinalbin (a) and sinigrin (b). 
 
Glucosinolates are stored in the plant vacuole, separately from the 
endogenous glucosinolate-hydrolyzing enzyme myrosinase (a β-D-
thioglucosidase)[126]. Upon cell rupture, myrosinase can come into 
contact with the glucosinolates and the enzymatic degradation is 
initiated, resulting in a variety of breakdown products (Fig. 12). 
In a first step, the enzyme cleaves the glucosinolate to give β-D-
glucose and an unstable thiohydroximate-O-sulfonate. 
The aglucon is then transformed to the isothiocyanate in the so-
called Lossen rearrangement, or decomposes to the corresponding 
nitrile and molecular sulfur.  
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Fig. 12.  Formation of enzymatic-breakdown products of glucosinolates. 
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Presently, glucosinolate-derived isothiocyanates, are attracting much 
scientific interest for their numerous biological and pharmacological 
effects, and for their useful applications in many aspects of human 
health[127]. It is worthy to note that there is an intriguing overlapping 
between many biological effects attributed to some Brassicaceae and 
those exhibited by the gasotransmitter H2S. Nevertheless, the 
possibly existing H2S-releasing potential of this class of natural 
compounds has never been described.  
To date, no specific investigation has been focused on the 
isothiocyanate functional group as a potential source of H2S, and its 
properties of H2S-donor and H2S-dependent effects on biological 
tissues are unexplored, even if an isothiocyanate derivative (4-
hydroxyphenyl isothiocyanate) has been reported as an example of 
potential H2S-releasing side-chain of multitarget anti-inflammatory 
agents in a recent patent[128]. 
Thus, some important isothiocyanates have been selected: allyl 
isothiocyanate (AITC), highly present in black mustard, Brassica 
nigra, 4-hydroxybenzyl isothiocyanate (HBITC), highly present in 
white mustard, Sinapis alba, and benzyl isothiocyanate (BITC), highly 
present in garden cress, Lepidium sativum. (Fig. 13). Moreover, the 
glucosinolate sinigrin (SIN, precursor of AITC) has been also 
selected. The evaluation and exploitation of the isothiocyanate 
moiety from other aryl isothiocyanates has been evaluated as well:  
phenyl isothiocyanate (PhNCS) and  p-carboxy-phenyl isothiocyanate 
(PhNCS-COOH) were selected (Fig. 14). 
The possible H2S-releasing activity of the selected compounds has 
been investigated by a reliable amperometric approach which was 
already used for analogous studies[114,118]. 
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Fig. 13. Chemical structures of allyl isothiocyanate (AITC), benzyl isothiocyanates 
(BITC), p-hydroxy-benzyl isothiocyanate (HBITC), sinigrin (SIN). 
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Fig. 14. Chemical structures of phenyl isothiocyanate (PhNCS) and 4-
carboxyphenyl isothiocyanate (PhNCS-COOH) 
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1.11. Mast cells 
 
Focusing on inflammation, mast cells are mainly considered 
regulatory cells in the hypersensitivity reaction, which finally release 
pro-inflammatory mediators by degranulation. Nevertheless, the 
importance of H2S in regulating mast cell degranulation process and 
thus, the subsequent inflammatory events, has not been studied. 
Mast cells have long been known to play a critical role in 
inflammatory and allergic reactions[129,130]. Recently, they have 
gained new importance as immunoregulatory cells with the 
discovery that they are a major source of cytokines and 
chemokines[130]. Given the anti-inflammatory activity of H2S, in this 
experimental work I evaluated the effect of H2S-donors in mast cell 
degranulation and, in particular, the protective role of H2S-donors in 
mast cell pro-inflammatory-mediator release. 
It is widely recognized that mast cells and basophils are essential 
effector cells in the elicitation of allergic response and resident 
multi-effector cells in the IgE-mediated hypersensitivity reactions.  
They are  mainly activated through the interaction of specific 
receptors, expressed on their cell surface, with secretagogues. This 
interaction initiates a series of biochemical events resulting in the 
release of biologically active mediators. The major mechanism for 
the stimulation of these cells is the interaction of antigen with IgE, 
which in turn is bound to its high-affinity receptor, FcεRI, on the cell 
surface. Such activation results in the release of preformed 
mediators from granules and the generation of newly synthesized 
mediators, such as the products of arachidonic acid metabolism and 
cytokines. 
 
1.11.1. FcεRI-induced mast cell activation 
 
The activation of mast cells is initiated when a multivalent antigen 
(allergen) interacts with the specific IgE antibody attached to the cell 
membrane via the high affinity IgE receptor (FcεRI). When FcεRI-
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associated IgE molecules bind the allergen, FcεRI receptors 
aggregate[129]. 
It is known that the expression of this receptor is related to the 
serum IgE concentration[131]. High “constitutive” levels of FcεRI 
expression are restricted to mast cells and basophils, and this feature 
helps to explain the unique role of mast cells as tissue-based effector 
cells in allergic inflammation.  
FcεRI has a tetrameric structure composed of a single IgE-binding α 
chain, a single β chain, and 2 identical disulfide-linked γ chains[132]. 
All 3 subunits must be present for efficient cell surface expression in 
rodents, but human cells can express FcεRI in the absence of the β 
chain[133]. In humans, the FcεRI expressed by hematopoietic cells, 
other than mast cells and basophils, consists of only the αγ2 
form[134]. The γ-subunits are important for initiating tyrosine-kinase-
cascade downstream of the receptor.  
Indeed, each γ subunit contains immunoreceptor tyrosine-based 
activation motifs (ITAMs)[130,135], which are phosphorylated by Lyn, a 
kinase belonging to the Scr kinases family. Phosphorylated ITAM 
activates Syk kinases and its translocation. This activation leads to 
the phosphorylation of the adaptor molecule LAT (linker for 
activation of T-cells). LAT regulates the macromolecular complex 
constituted by many proteins, such as PLCγ[136]. IP3 and 
diacylglycerol (DAG) formation through the pathway Lyn-LAT-PCLγ, 
is involved in mediators release[137]. Aggregation of FcεRI also 
rapidly activates Fyn kinase, whose activity is important for 
phosphorylation of the adaptor known as Grb2 associated binder-
like protein 2 (Gab2) and activation of PI3 kinase (PI3K) activity. 
Both Fyn and Lyn co-immunoprecipitate with FcεRI but although Lyn 
is known to directly interact with the tretraspanning β chain, it is not 
known whether Fyn directly or indirectly interacts with FcεRI[138]. 
Lyn kinase negatively regulates the activity of Fyn but positively 
regulates the activation of Syk. Fyn kinase positively regulates Gab2 
and its association with PI3K and is essential for initiation of the 
degranulation response. Signals generated by the two distinct 
adaptor complexes (LAT and Gab2) synergize to support novel PKC 
activation and calcium signals.  
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Stimulation of PI3K results in transient accumulation of micromolar 
levels of PIP3 and PIP2. In addition PI3K is important in the 
regulation of intracellular Ca++, which may be attained by PLC-γ 
activation. 
MAPK (Mitogen-Activated Protein Kinase) pathways including ERK 
1/2, JNK (c-Jun N-terminal kinase) and p38 MAPKs are also activated 
by antigen-IgE ligation of FcεRI. An important role for these MAPK 
pathways in mast cell function is predicted based on the ability of 
ERK1/2, JNK and p38 to regulate the transcriptional activity of 
cytokine genes[139] (Fig. 15).  
 
  
Fig. 15. A model of structure and functional coupling of the high affinity receptor 
for immunoglobulin E (FcεRI) to early signaling events[140]. 
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1.11.2. Ca++-induced mast cell degranulation 
 
The aggregation of FcεRI occupied by IgE is sufficient for initiating 
downstream signal transduction events that activate the mast cells 
or basophils to degranulate and secrete mediators and cytokines due 
to a final increase of Ca++ (Fig. 15)[138,141].  In fact, the exocytotic 
release of granules, after the fusion with plasma-membrane, depends 
on the increase in cytosolic Ca++ levels and the activation of PKC[142]. 
The increase of cytosolic Ca++ is associated with release from 
intracellular stores and influx of external Ca++[143,144] by a 
mechanism, originally referred to as capacitative calcium entry 
(CCE). Recently, this influx is often referred to as store-operated 
calcium entry (SOCE), in which depletion of intracellular stores of 
Ca++ leads to entry of Ca++[145]. Ca++-entry was initially thought to 
occur through a calcium-release activated calcium current (ICRAC or 
CRAC), a Ca++-selective current of low conductance that requires 
external Ca++ to achieve maximal conductance. Nevertheless, it 
appears unlikely that CRAC is the sole mechanism for conductance of 
Ca++ as early studies of calcium-dependent exocytosis clearly 
demonstrated that it stimulated mast cell degranulation. 
Although the movement of Ca++, especially due to the activation of 
CRAC channels, plays an important role in mast cell activation[146,147], 
the movement of K+ can be just as important because it can affect the 
extent of Ca++ entry and thus the downstream release of 
mediators[146,148]. Available evidence has revealed that the activation 
of outward K+ current correlates with the activation of CRAC current 
in both time and amplitude in mast cells[147] and that the KCa channel 
current enhances the release of mediators[149]. Furthermore, in 
contrast to excitable cells, mast cell membrane hyperpolarization is 
required to support Ca++ entry[150]. Therefore, a fast 
hyperpolarization and an increase in intracellular Ca++ levels[151] 
show that K+ and Ca++ are intrinsically linked, and that K+ channel 
activation may be even more critical than the entry of Ca++ in the 
control of mediator release. 
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1.11.3. Mediator release  
 
Within seconds or minutes of exposure to allergen, mast cells and 
basophils can undergo regulated secretion of their cytoplasmic 
granules and contents by exocytosis. The terms degranulation, 
secretion, and exocytosis are often used interchangeably but have 
subtle variations in meaning.  
Degranulation refers to the loss or release of granules and is most 
often associated with mast cells and basophils, both of which are 
characterized by their large intracellular granules. Mast cells exhibit 
all forms of release, but are perhaps best known for their rapid 
secretion of granules (degranulation) that contain large stores of 
pre-formed mediators[140]. Degranulation may be induced by many 
factors, such as physical destruction (high temperature, mechanical 
trauma, ionizing irradiation, etc.); chemical substances (toxins, 
venoms, proteases); endogenous mediators, including tissue 
proteases, cationic proteins derived from eosinophils and 
neutrophils.  
Both mast cells and basophils contain special cytoplasmic granules 
which store mediators of inflammation. Thus, the most significant 
difference between mast cells and basophils consists in their 
responsiveness to some activating agents, neuropeptides, and 
cytokines, which can induce mediators release independently of IgE, 
modulate FcεRI-dependent activation, or both[152-155]. Both cells 
express on their surface the receptor that binds with high affinity the 
Fc portion of the IgE antibody[156]. 
Basophils differ from mast cells in terms of morphology, and in that 
there are fewer, but larger granules in basophils. Unlike mast cells, 
basophils have little proliferative capacity, but maintain the same 
array of released mediators; these can be divided into three 
categories: 
- preformed mediators (biogenic amines, such as histamine and 
serotonin, proteases, lysosomal enzymes, such as β-
hexosaminidase, some cytokines, as TNF, IL-4 and SCF);  
- newly synthesized lipid mediators (e.g. prostaglandin D2 
[PGD2] and leukotriene 4 [LTC4]);  
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- cytokines/growth factors (e.g. IL-3, IL-13, VEGF-A, GM-CSF, 
TNF) and chemokines (e.g. CCL2/MCP-1 and IL-8/CXCL8)[157] 
 
Preformed mediators, stored in secretory granules and secreted upon 
cell activation, include a biogenic amine, typically histamine, 
proteoglycans, either heparin, over-sulphate chondroitin sulphates 
or both, and a spectrum of neutral proteases. Histamine, alone or in 
synergy with other mediators, contributes to the core features of 
inflammation, namely blood vessel dilatation and permeation, tissue 
swelling, raised temperature, pain and irritancy[157,158]. Released 
histamine acts at H1, H2, H3 and H4 receptors on cells and tissues 
and evokes a biphasic rise of cytosolic Ca++ concentration in mast 
cells, consisting in a release of intracellularly stored Ca++ followed by 
an influx from the extracellular space. Ultimately, histamine has a t1/2 
of ~ 1 minute in the extracellular fluid and is degraded by histamine 
N-methyltransferase and by diamine oxidase. Although it is difficult 
to measure histamine in serum due to its short half-life, histamine 
and its metabolites can be measured in urine.  
The proteoglycan, which imparts the metachromatic staining 
characteristic of mast cells when exposed to certain basic dyes such 
as toluidine blue, has two functions: it may package histamine and 
basic proteins into secretory granules, and in human mast cells it 
appears to regulate the stability of the protease called tryptase. 
Another important mediator released when degranulation occurs is 
β-hexosaminidase (β-hex). This is a granule-associated enzyme, an 
exoglycosidase that is released in parallel with histamine and has 
been extensively used to monitor mast cell degranulation. Its role in 
inflammation is not known, but it has been hypothesised that it could 
act in concert with tryptases and chymases for the degradation of 
glycoproteins and proteoglycans of the ECM (an important event 
during the remodelling of the inflamed tissue). The enzyme β-hex 
shows optimal activity at low pH (pH = 4.5), a typical condition 
during inflammatory processes. Furthermore, β-hex is commonly 
used as a marker for degranulation in both RBL-2H3 cells and mast 
cells. 
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In addition to preformed mediators, mast cells can generate 
mediators de novo. These are absent in the resting mast cells, and are 
typically produced during IgE-mediated activation, and consist of 
arachidonic acid metabolites, principally leukotriene C4 (LTC4), 
prostaglandin D2 (PGD2) and cytokines. As a consequence of mast 
cell activation, other inflammatory cells are recruited and activated, 
and a cascade of inflammatory mediator production and release is 
set in motion. For example, cysteinyl leukotrienes formed via the 
lipoxygenase pathway of arachidonic acid oxidation, are potent 
bronchoconstrictors, induce mucus secretion and contribute 
substantially to airway narrowing in asthma[159]. 
Mast cells are a rich source of diverse cytokines that are synthesized 
de novo upon cell activation or stored ‘ready-to-go’ in the secretory 
granules[160,161 ]. The list of cytokines and chemokines released from 
mast cells upon IgE-dependent and IgE-independent activation is 
extensive, but of particular interest  is the production of TNF-α, IL-4, 
IL-5 and IL-6.  
Due to synthesis and release of diverse types of inflammatory 
mediators, immune cells may elicit pathophysiological changes in 
various organs, leading to the development of different syndromes. 
The biogenesis of mast cell granules involves the regulated fusion of 
what are called unit granules (small fusogenic granules)[162]. These 
early unit granules buds from the trans-Golgi region and fuse to 
generate progranules in a region delimited by the outermost Golgi 
cisternae, rough endoplasmic reticulum (ER), and mature granules in 
the cytoplasm. The volumes of progranules are multiples of unit 
granules (i.e., volume of progranule created by three-unit granules is 
three times unit granule volume). Progranules leave this zone as 
immature granules and become mature through a fusion process 
with other immature or mature granules. A process called 
“condensation” reduces the granule volume and organizes the 
contents, generating various sizes of mature granules[163].  
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1.12. Cardiac mast cells and renin release 
 
The mast cell-like cell line RBL-2H3 (rat basophilic leukemia) is not 
universally considered a predictive model of native mast cells. 
Although there are many advantages in using immortalized cell lines, 
including homogeneity and ease of culture, experimental studies 
have shown mast cell-like lines to be only marginally representative 
of mature, tissue-bound, non-transformed mast cells, and differences 
exist in adherence, receptor expression, and enzyme content. 
Therefore, characterizing the activity of the H2S-donor on the 
degranulation of authentic mast cells was a necessary step aimed at 
evaluating the potential therapeutic effects of H2S-donors and their 
subsequent translational application in mast cells-derived diseases.  
To address this aim, further experimental investigations were 
focused to assess the anti-degranulating properties of H2S released 
from donors in specific cell lines. In fact, even though many studies 
have been dedicated to the role of H2S in the immune system, in 
particular in macrophages[164] and lymphocytes[165], up to now very 
few research groups have assessed the effects of H2S in mast 
cells[166]. 
As previously stressed, mast cells are key players in several allergic 
reaction and play a central role in the pathogenesis of immediate 
hypersensitivity and mastocytosis, but are also implicated in host 
responses to pathogens, autoimmune diseases, fibrosis, and wound 
healing. 
Briefly, mast cells arise from CD34+-pluripotential hematopoietic 
progenitor cells in the bone marrow; they are tissue-resident 
inflammatory cells that respond to signals of innate and adaptive 
immunity with immediate and delayed release of inflammatory 
mediators.  
Mast cell precursors circulate in the blood and migrate into all 
vascularized tissues, where they complete their maturation under 
local microenvironment factors[167,168]. Normally, the localization is 
restricted to strategic anatomic sites, especially where foreign 
environmental agents attempt to invade the host, and they are 
exposed to the external environment, such as skin, respiratory tract, 
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gastrointestinal tract. Such a strategic position well explains why 
mast cells are the first component of the immune system capable to 
interact with antigens, pathogens, toxins and radiations[169]. 
For several decades mast-cell research was addressed to the 
understanding of the pathophysiology of allergic disease and  
reached the conclusion that mast cells operate as cellular mediators 
of allergy. Simultaneously, there has been also an increased 
understanding of mast cell biology in general, which raised a wider 
and newer view about potential functions of mast cells unrelated to 
allergy. Indeed, in the past decades mast cells have been recognized 
as cells that not only regulate allergy, but also many tissues 
functions, such as wound healing, homeostasis and regulation of 
innate and adaptive immune responses[130]. Moreover, increasing 
evidence suggests that mast cells play a key role in I/R injury[170]. 
Zhang et al.[171] showed that there is increased mast cell density 
during progressive myocardial fibrosis and diastolic cardiac 
dysfunction. 
Mast cells degranulation associated with I/R is different from the 
well-known FcεRI-dependent pathway. In fact, I/R-induced mast 
cells degranulation could be driven by extracellular pathways[172] 
and intracellular pathways triggered by substances produced by the 
mast cells themselves, such as ROS[173] or toxic aldehydes[174]. 
Indeed, mature mast cells are a normal component of connective 
tissue, but are also present in parenchyma, as in the heart, where 
they are closely apposed to vessels and nerves[168,175].  
Recently, cardiac mast cells have been shown to be a novel and 
previously undescribed source of renin in human and rodent 
myocardium. Many studies were carried out to investigate the 
presence and the role of this protease, and it was confirmed that it 
can be synthesized, stored and secreted upon degranulation by 
cardiac mast cells[175-177]. 
It was also demonstrated by immunostaining experiments,  Western 
blots and pharmacological procedures that renin is present in mast 
cells, and it derives from a de novo biosynthesis in situ, and not from 
an up take of circulating renin[175]. 
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In cardiac mast cells, renin is the rate-limiting enzyme of the renin-
angiotensin system (RAS) cascade. It cleaves the angiotensinogen 
present in the interstitial space, to angiotensin I (Ang I)[178]. Then, 
Ang I, an inactive precursor peptide, is converted to Ang II by 
angiotensin-converting enzyme (ACE). Ang II activates angiotensin II 
receptors type 1 (AT1), expressed in cardiac sympathetic nerves[179], 
and potentiates Na+/H+ exchanger (NHE) activity[179]. This serves to 
increase intraneuronal Na+ to a level that triggers excessive carrier-
mediated norepinephrine (NE) release[180], leading to arrhythmias 
and cardiac dysfunctions[176] (Fig. 17).  
 
  
Fig. 17. Model of local cardiac RAS and its activation in myocardial ischemia. 
AT1R, AT1 receptor; NHE, Na+/H+ exchanger; NET, NE transporter 
 
Mast cells also have the ability to respond to a wide range of stimuli. 
The activation of cardiac mast cells could be triggered by many other 
factors, among which ROS[173], toxic aldehydes[174], bradykinin[181], 
calcium and others.  
Extracellular nucleotides are important autocrine/paracrine 
mediators in various tissues. Increasing evidence suggests that 
extracellular ATP functions as a stress-responsive molecule. Indeed, 
ATP is one of several agonists which elicit Ca++-dependent exocytotic 
degranulation of mast cells, causing the release of histamine and 
other mediators of immediate hypersensitivity[182]. Cardiac mast 
cells are juxtaposed to sympathetic/purinergic nerve terminals, 
ATP 
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which are responsible for the release of neurotransmitter ATP[183] in 
stress condition or during I/R, initiating a vicious cycle that amplifies 
renin release thus activating a local RAS. The release of renin, as a 
consequence of ATP-induced degranulation, was also demonstrated 
to occur in mast cells[184](Fig. 17). 
Previously, H2S has been reported to be an important endogenous 
gaseous transmitter that is implicated in a myriad of physiological 
and pathological conditions. It has been reported to protect against 
heart failure and prevent hypertrophy via induction of anti-oxidant 
responses, inhibiting apoptosis and promoting angiogenesis[166]. 
Moreover, H2S induces protection against cardiac mast cell 
infiltration and renin release[166]. 
Liu et al. were the only research group that investigated the activity 
of H2S in cardiac mast cells and its potential effect in reducing renin 
release. In this thesis, I investigated whether or not H2S is able to 
play a protective role in mast cell degranulation, thus reducing the 
damage caused by I/R. For this, I used two different cell lines. Renin 
and β-hex were measured as reliable markers of degranulation both 
in BMMC and HMC-1 cells. The cells where challenged with non-
antigenic and antigenic stimuli, when possible. 
 
1.13. Ischemia/reperfusion injury and mast cell 
degranulation. 
 
Heart failure is the heart's inability to supply enough blood to meet 
the needs of the body. Worldwide, heart failure has become the most 
common discharge diagnosis in patients 65 years or older and 
treatment remains insufficient. Therefore, the investigation of 
therapeutic options to attenuate cardiac dysfunction in heart failure 
remains clinically relevant and critical. 
A large number of laboratories have clearly demonstrated the 
cardioprotective actions of H2S in both acute myocardial infarction 
and heart failure[185]. The mechanisms responsible for these 
protective effects include the downregulation of oxidative stress 
responses, modulation of mitochondrial respiration, attenuation of 
apoptosis, and increasing vascular growth and angiogenesis. H2S is 
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known to activate multiple and diverse pathways simultaneously 
and exhibits crosstalk with the NO and CO signaling pathways to 
amplify a cytoprotective response. The opening of KATP channels in 
myocardium has been seen to play a pivotal role in cardioprotection 
during irreversible I/R injury, which is specifically seen in cardiac 
ischemic preconditioning[67]. H2S also plays a critical role in the 
protection of mitochondria during ischemic states in a manner that 
significantly attenuates cell death and apoptosis[186]. Establishing 
this state can preserve mitochondrial function by reducing oxidative 
stress and mitigating apoptotic signaling. This renders H2S 
particularly protective against myocyte injury in settings such as 
acute myocardial I/R. 
H2S is spontaneously generated from the H2S-donor, NaHS. It was 
observed in the perfused rat heart preparation that NaHS 
concentration-dependently limited the size of infarction induced by 
left coronary artery ligation, and this protective effect was abolished 
by KATP channel blockers glibenclamide and 5-hydroxydecanoate (5-
HD)[71]. 
Therefore, in the heart H2S and its donors cause a negative inotropic 
and chronotropic action by activating sarcKATP and mitoKATP and 
inhibiting L-type Ca++ channel activity, and exert cardioprotection 
against I/R injury. 
Mast cells are known to proliferate in the heart and have been 
implicated in myocardial ischemia[187], atherosclerosis[188], heart 
failure[189] and cardiac anaphylaxis. Mast cell degranulation during 
I/R differs from the well-known allergen-triggered high affinity IgE 
receptor pathway. Instead, mast cell degranulation is driven by both 
an extracellular pathway mediated by a series of G protein-coupled 
receptors (GPCR)[172] and intracellular pathway triggered by 
substances produced by mast cells themselves, such as ROS[173]. 
Many chemicals which are stored in the granules of mast cells or 
synthesized de novo can be released during I/R and promote cellular 
injury. Moreover, it is also demonstrated that I/R enhances ATP 
levels and cardiac renin release in the heart and that both cardiac 
renin and ATP are pivotal in the response to I/R[174,176]. 
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In the heart, the close proximity of mast cells to nerves may be 
particularly relevant to the generation and progression of 
arrhythmias and other types of dysfunction. In fact, the strategic 
perineuronal location of cardiac mast cells in addition to their 
accumulation in pathological conditions may promote the 
development of myocardial dysfunctions due to local RAS activation. 
In fact, during I/R nerve endings release NE which is enhanced by 
Ang II. (Fig. 17) Of note, the renin-angiotensin-system can cause 
vasoconstriction and NE can cause arrhythmias. Using a mast cell 
stabilizer, reperfusion-induced arrhythmias are abolished[176].  
In the last part of my study, in order to evaluate whether the 
cardioprotective effects of H2S are due to a direct action on 
myocardial cells or to resident mast cells, ex vivo experiments have 
been carried out in isolated rat and mouse hearts models. Cardiac 
parameters were measured and evaluated in order to determine the 
degree of cardioprotection. 
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Chapter 2 
 
H2S-donors 
 
An amperometric approach was used to determine the potential H2S-
releasing properties of compounds belonging to different chemical 
classes. This method allows to have a real-time 
qualitative/quantitative evaluation of the H2S-release. Thus, in order 
to obtain a satisfactory description of the kinetics of the H2S 
generation with a slow and progressive process, the parameters of 
Cmax (maximal concentration of H2S at the steady state) and thc (time 
required to reach a concentration = 50% of Cmax) were extrapolated 
from the curves H2S-release vs time.  
The mechanisms through which the gaseous molecule is released 
depends on the chemical structure of the H2S-donor and in 
particular, this reaction requires the presence of organic thiols, such 
as reduced glutathione[26]. For this reason, the experiments were 
both performed in the presence or in the absence of a L-cysteine 
solution, the endogenous substrate for the H2S production. In this 
way, a reliable reproduction of the thiols present in the biological 
environment was created.  
Currently, organic H2S-donors suffer a number of limitations 
including structural constraints and uncontrolled H2S release 
kinetics. Moreover, the in vivo function of H2S is coupled to its local 
concentration; therefore, the compounds able to release H2S 
endowed with an higher Cmax in the presence of L-cysteine rather 
than without L-cysteine could be viewed more manageable 
compounds. In fact, the precise control over the rate of H2S release 
from donor compounds is fundamental. Although, finding 
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compounds whose H2S release is limited only to the biological 
ambient is an innovative strategy in the drug discovery field. 
 
2.1. Methods 
 
2.1.1. Amperometry  
 
The characterization of the potential H2S-generating properties of 
the tested compounds has been carried out by amperometric 
approaches, through an Apollo-4000 Free Radical Analyzer (WPI) 
detector and H2S-selective mini-electrodes. The experiments were 
carried out at room temperature. Following the manufacturer's 
instructions, a “PBS buffer 10 ×” was prepared (NaH2PO4•H2O 1.28 g, 
Na2HPO4•12H2O 5.97 g, NaCl 43.88 g in 500 mL H2O) and stocked at 
4 °C. Immediately before the experiments, the “PBS buffer 10 ×” was 
diluted in distilled water (1:10), to obtain the assay buffer (AB); pH 
was adjusted to 7.4. The H2S-selective mini-electrode was 
equilibrated in 10 ml of the AB, until the recovery of a stable 
baseline. Then, 100 μl of a dimethyl sulfoxide (DMSO) solution of all 
the tested H2S-releasing compounds was added (final concentration 
of the tested H2S-donors 1 mM; final concentration of DMSO in the 
AB 1%). The eventual generation of H2S was observed for 15 min. 
When required by the experimental protocol, L-Cysteine (4 mM) was 
added, before the H2S-donors. The correct relationship between the 
amperometric currents (recorded in pA) and the corresponding 
concentrations of H2S was determined by opportune calibration 
curves, which were previously obtained by the use of increasing 
concentrations of NaHS (1 μM, 3 μM, 5 μM, 10 μM) at pH 4.0. 
The curves relative to the progressive increase of H2S vs time, 
following the incubation of the tested compounds, were analysed by 
the equation 
 
Ct=Cmax−(Cmax•e−k•t) 
 
where Ct is the instant concentration at time t, and Cmax is the highest 
concentration achieved in the recording time. The constant k is 
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0.693/thc, where thc (time for half concentration) is the time required 
to reach a concentration = ½ Cmax. The values of Cmax and thc were 
calculated by a computer fitting procedure (software: GraphPad 
Prism 5.0) and expressed as mean ± standard error; at least 5 
different curves were performed for each compound. ANOVA and 
Student t test were selected as statistical analysis, P < 0.05 was 
considered representative of significant statistical differences. 
 
2.1.2. Spectrophotometry 
 
At the end of the above amperometric approach, an usual 
spectrophotometric method has been also used, in order to have 
further indication about the H2S-releasing properties of the tested 
compounds. Briefly, at the end of the amperometric recording, 800 μl 
of the AB containing the tested agents (in the absence or in the 
presence of L-Cysteine) were mixed with 50 μl of N,N-dimethyl-
phenylen-diamine (Sigma-Aldrich) (20 mM in hydrochloric acid 
solution 7.2 M) and 50 μl of FeCl3 (Sigma-Aldrich) (30 mM in 
hydrochloric acid solution 1.2 M). After 20 min, required for the 
methylene blue formation, the absorbance at 670 nm has been read 
through a spectrophotometer Novaspec Plus (Amersham 
Biosciences). The spectrophotometric measurements were 
converted to the corresponding concentrations of H2S, by opportune 
calibration curves previously obtained by the use of increasing 
concentrations of NaHS (1 μM, 3 μM, 5 μM, 10 μM). The values of Cmax 
were expressed as mean ± standard error, from at least 5 different 
measurements.  
 
2.1.3. Gas chromatography/mass spectrometry 
 
The confirmation of the H2S formation was also verified by 
headspace-gas chromatography–mass spectrometry analysis. 100 μl 
of DMSO solution of PhNCS-COOH was added (final concentration of 
the tested H2S-donor 1 mM; final concentration of DMSO in the AB 
1%), to 10 ml of the AB, in the presence or in the absence of L-
Cysteine (4 mM). 5 ml of the above solutions was stored in 6 ml glass 
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screw cap headspace vials (Agilent Technologies) with PTFE/silicone 
pre-slit septa. All headspace equilibrations were performed at 25 °C 
for 30 min. 500 μl of headspace gas of each sample was directly 
injected into a 6% cyanopropyl phenyl siloxane and 94% 
dimethylpolysiloxane capillary column (DB-624, 60 m length, 0.25 
mm internal diameter, 1.4 μm film thickness, Agilent Technologies) 
of the gas chromatograph (Trace GC Ultra, Thermo Electron 
Corporation) coupled to a quadrupole mass spectrometer (Trace 
DSQ, Thermo Electron Corporation) operated in the positive electron 
impact ionisation (70 eV). Chromatograms were collected in total ion 
current (TIC) acquisition mode (18–200 amu). The oven 
temperature programme was 30 °C for 5 min, 15 °C min−1 to 260 °C, 
10 min hold. The temperature of the injector was set at 200 °C. 
Helium (constant pressure 210 kPa, split flow of 10 ml min−1) was 
used as carrier gas. 
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2.2. Results  
 
NaHS 
The addition of NaHS 1 mM at pH 7.4 both in the presence or in the 
absence of L-cysteine was followed by an immediate formation of a 
very high concentration of H2S (about 200 μM), according to its 
physicochemical properties[90]. Thereafter, the concentration of H2S 
showed a rapid fall in the first minutes after the addition of NaHS, 
followed by a slower and apparently constant decline in the 
remaining time (Graph. 1). The H2S-release from NaHS was not 
influenced by the presence of L-Cysteine. 
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Graph. 1. Amperometric recording of H2S release. Curve describes the increase of 
H2S concentration, with respect to time, following the incubation of NaHS 1 mM at 
pH 7.4 without L-cysteine. 
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GYY4137 
The release of H2S was evaluated from the water-soluble molecule 
GYY4137, selected as a reference H2S-donor. In the presence of L-
cysteine at pH 7.4, 1 mM GYY4137 shows a slow kinetic of release of 
the gasotransmitter with a value of Cmax equal to 10.3 ± 2.6 µM and a 
thc of 2.5 ± 0.8 min. Contrarily, when GYY4137 is added into the same 
buffer without L-cysteine a negligible amount of H2S was measured 
(Graph. 2). 
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Graph. 2. Amperometric recording of H2S release. Curves describe the 
increase of H2S concentration, with respect to time, following the incubation of 
GYY4137 1 mM at pH 7.4 without L-cysteine (white squares) and in the presence 
of L-cysteine (black squares). 
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IS-176 
The release from the thioamide IS-176 has been measured in the 
assay buffer alone, in presence of 4 mM L-cysteine and 4 mM 
reduced glutathione (GHS), in order to evaluate the possible 
influence of other organic thiols. In the assay buffer alone IS-176 did 
not show significant H2S-releasing properties, which are instead 
exhibited in a L-cysteine-dependent manner (Graph. 3). Like L-
cysteine, even GSH triggered a significant, but slower, release of H2S 
from the selected thioamide. This first phase of the experimental 
work showed an L-cysteine-dependent mechanism of H2S-releasing 
properties. Such a profile has been suggested to be convenient for 
the development of a potential drug, as this feature may provide a 
selective H2S-release in a biological environment (i.e., in the 
presence of endogenous organic thiols such as L-cysteine, GSH, etc.).  
The release of H2S from IS-176 1 mM is slow and constant in time 
with values of Cmax about 3.60±0.6 µM and a thc value of 2.1 ± 0.2 min. 
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Graph. 3. Amperometric recording of the release of H2S. Curves describe the 
increase of H2S concentration, with respect to time, following the incubation IS-
176 in the assay buffer, in the absence or in the presence of L-cysteine (squares) 
and GSH (black triangles). Points are mean ± SD. 
 
  
 
 
54 
 
Diallyl disulfide 
The release of H2S from diallyl disulfide (DADS) is reported to be a 
process which requires the presence of organic thiols such as 
reduced glutathione[26]. For this reason the experiments were also 
performed in the presence of 4 mM L-cysteine. The incubation of the 
organic polysulfide DADS and the phosphinodithioate derivative 
GYY4137 led to a negligible formation of H2S in the absence of L-
cysteine; but, in the presence of this amino acid, the incubation of 
DADS was followed by a relatively slow formation of H2S, with Cmax of 
about 20 µM (Graph. 4). 
 
0 5 10 15
0
10
20
30
DADS 1mM - Cys
DADS 1mM + Cys 4mM
min
H
2
S

M
 
Graph. 4. Amperometric recording of the release of H2S. Curves describe the 
increase of H2S concentration, with respect to time, following the incubation of 
DADS and GYY 4137 in the assay buffer, in the absence or in the presence of L-
cysteine.  Points are mean ± SD. 
 
The H2S-releasing capacity is a pharmacologically relevant feature, 
already attributed to naturally occurring compounds, such as the 
diallyl polysulfides of garlic, but never reported for natural 
isothiocyanates.  
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Isothiocyanates 
As concerns the isothiocyanates tested in the present work, the 
presence of L-cysteine caused a significant improvement of the H2S-
releasing properties of AITC (Graph. 5). Contrarily, in the absence of 
L-cysteine, the incubation of AITC led to the formation of low 
concentrations of H2S. Such a L-cysteine-dependent release of H2S, 
probably due to the nucleophilic behavior of the amino acid, has 
been already observed for well-known H2S-donors, such as 
GYY4137, DADS, and many synthetic thioamides and 
isothiocyanates[114,118]. In contrast, the allyl glucosinolate SIN 
showed a lack of significant H2S-releasing effects in both the 
experimental conditions (absence or presence of L-cysteine) (Graph. 
5). 
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Graph. 5. Curves describe the increase of H2S concentration, with respect to time, 
following the incubation of SIN (triangles) and AITC (squares) in the assay 
buffer, in the absence or in the presence of L-cysteine. Points are mean ± SD. 
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Among the few selected secondary metabolites of Brassicaceae, 
HBITC was the most effective H2S-donor, exhibiting significant and 
remarkable H2S-release. In particular, in the absence of the L-
cysteine, the incubation of HBITC was followed by a slow generation 
of appreciable levels of H2S (about 10 µM) (Graph. 6). BITC exhibited 
the weakest (albeit significant) H2S-releasing properties. In 
particular, BITC behaved as very poor H2S-donor both in the absence 
and in the presence of L-cysteine (Graph. 6). 
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Graph. 6.  Amperometric recording of H2S released from BITC and HBITC. The 
curves describe the increase of the H2S concentration with respect to time, 
following the incubation of BITC (triangles) and HBITC (squares), either in the 
absence or in the presence of L-cysteine. Points are mean ± SD. 
 
Synthetic isothiocyanates, such as PhNCS and PhNCS-COOH, 
incubated in the absence of L-Cysteine led to the formation of 
negligible amounts of H2S. In contrast, the presence of increasing 
concentrations of this amino acid lead to a well related increase of 
the H2S release from PhNCS, as clearly indicated by both the 
amperometric recordings (Graph. 7a) and the matched 
spectrophotometric measurements (Graph. 7b). In the presence of 
the highest concentration of L-Cysteine (4 mM), the incubation of 
PhNCS led to a slow (thc about 5 min) release of H2S (up to a Cmax of 
about 20 μM). 
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The presence of the 4-carboxy group (PhNCS-COOH) improved the L-
Cysteine-mediated H2S-release (Cmax of 35 μM, with L-Cysteine 4 
mM) without affecting the rate of the process (thc of about 5 min). 
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Graph. 7a. Amperometric recording of H2S released from PhNCS and PhNCS-
COOH. The curves describe the increase of the H2S concentration with respect to 
time, following the incubation of PhNCS (squares) and PhNCS-COOH (triangles), in 
the presence of L-cysteine. Points are mean ± SD. 
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Graph 7b. The histograms describe the H2S concentration, determined by 
spectrophotometric technique, after the incubation of 1 mM PhNCS in AB buffer, in 
the absence or in the presence of L-cysteine 4 mM. The vertical bars indicate the 
SEM. 
 
Moreover, PhNCS-COOH was selected for a further unequivocal 
demonstration of the generation of H2S by means of gas/mass 
chromatographic approaches. After the incubation of PhNCS-COOH 
 
 
58 
 
in the AB, in the presence of L-cysteine, H2S was clearly detected in 
the headspace of the vials. In contrast, no significant formation of H2S 
was revealed in the absence of L-cysteine (Fig. 8). 
 
 
Fig. 8. Extracted ion chromatograms at m/z 34 (H2S, RT = 3.11 min) of the assay 
buffer AB at pH = 7.4 spiked with DMSO (1%) in the absence of L-cysteine (A) and 
in the presence of L-cysteine 4mM (B);  AB added with DMSO (1%) and PhNCS-
COOH (1mM) in the absence of L-cysteine (C) and in the presence of L-cysteine 
4mM (D). 
Vehicle (DMSO 1%)
Vehicle (DMSO 1%) + L-Cys
PhNCS-COOH 1mM
PhNCS-COOH 1mM + L-Cys
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2.3. Discussion 
 
All the compounds were first submitted to an amperometric 
evaluation, which allowed to have a “real-time” determination of the 
H2S release and thus to perform a qualitative/quantitative 
description of the event. As shown in the graphs 1-7, the tested 
compound released H2S at different rates. Moreover, such release 
occurs when thiols are present in the assay buffer (L-cysteine 4 mM).  
In fact, the process of H2S release has been described to require the 
presence of organic thiols[26]. Consistently, the incubation of the 
compound without L-cysteine (or GSH) is supposed to lead to the 
formation of negligible amounts of H2S. 
NaHS (Graph 1) was considered a reference compound, used also for 
each experiment as a calibrator. The release of H2S from the sodium 
salt occurred both in the presence and in the absence of L-cysteine 
with high concentrations of the gas. Nevertheless, the steady state 
couldn’t be reached due to the quick elimination in the solution. In 
fact, the rapid fall of H2S concentration within 2 minutes perfectly 
shows the profile of the fast H2S-donor.   
In contrast, the thioamide derivate IS-176, showed a relatively slow 
and L-cysteine-dependent release of H2S comparable to the 
reference drug GYY4137 (Graph 2 and 3). In particular, that release 
was absent when it was incubated in the assay buffer alone. The 
presence in the molecule of the hydroxyl group in position 4 and the 
primary amino moiety led to a slight, albeit not significant, 
improvement of the H2S-release[118]. 
As concerns the natural polysulfide, in contrast to the fast release of 
the reference drug NaHS, DADS showed a slow mechanism of release 
of H2S solely in presence of L-cysteine (Graph 4). 
The incubation of all the isothiocyanates led to the formation of 
negligible amounts of H2S when the amperometric recording was 
taken in presence of the assay buffer alone. The enzymatic 
decomposition of sinigrin leads to the formation of AITC, glucose and 
sulfate ions. The aglicone moiety, AITC, showed a significant 
formation of H2S compared to the glucosinolate sinigrin in presence 
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of L-cysteine. The slight formation of H2S obtained with sinigrin 
suggests that the isothiocyanate moiety is preferable for the 
formation of the gas (Graph 5). 
In the absence of the L-cysteine, the incubation of HBITC was 
followed by a slow generation of appreciable levels of H2S. Notably, 
the co-presence of the amino acid led to a marked increase in the 
H2S-release from HBITC (Graph 6). The H2S-releasing properties of 
BITC, recorded in the presence of L-cysteine, were strongly 
comparable to those exhibited by DADS, but BITC behaved as a 
remarkable H2S-donor even in the absence of this amino acid (Graph 
6). 
Synthetic isothiocyanates, such as PhNCS and PhNCS-COOH, 
endowed with the 4-carboxy group, caused an increase of L-
Cysteine-mediated H2S-release, without affecting the slow rate of the 
process (Graph 6). The presence of L-cysteine brought to reach a 
steady state concentration of H2S, avoiding the dangerous side 
effects typical of rapid H2S-donors. 
The generation of H2S from PhNCS-COOH, recorded by amperometric 
approaches, was further confirmed by suitable spectrophotometric 
and gas/mass chromatographic determination. 
 
2.4. Conclusions 
 
Given the relevance of identifying compounds with a slow H2S-
releasing rate, this first phase of the experimental work led to the 
identification of a number of original H2S-releasing compounds, with 
natural and synthetic origin, that showed an L-cysteine-dependent 
mechanism. Such a profile has been suggested to be convenient for 
the development of a potential drug. In fact, this feature may provide 
a selective H2S-release in a biological environment (i.e., in the 
presence of endogenous organic thiols such as L-cysteine, GSH, etc.) 
leading to an increased H2S production which can modulate a given 
pathophysiological condition. 
Further experiments have been performed to evaluate the properties 
of H2S, released from the above mentioned compounds, in 
inflammatory conditions in in vivo and in vitro models.  
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Chapter 3 
 
Effects of H2S-donors on the 
degranulation of RBL-2H3 
 
3.1. Introduction 
 
Mast cells have long been known to play a critical role in 
inflammatory and allergic reactions[129,130]. Recently, they have 
gained new importance as immunoregulatory cells with the 
discovery that they are a major source of cytokines and 
chemokines[130].   
The major mechanism for the stimulation of these cells is the 
interaction of antigen with IgE bound to its high-affinity receptor, 
FcεRI, on the cell surface. Such activation results in the release of 
preformed mediators from granules and the generation of newly 
synthesized mediators, such as the products of arachidonic acid 
metabolism and cytokines. The release of β-hexosaminidase, a 
reliable marker of mast cell degranulation was 
spectrophotometrically determined after incubation of H2S-donors. 
Different molecules belonging to heterogeneous chemical classes 
were tested in order to understand the role of H2S released in the 
inhibition of mast cell activation. In particular, in this chapter are 
discussed the effects of the series of H2S-donors on a particular and 
well-known model of degranulation, by using the rat basophilic 
leukemia cell line. 
 
 
62 
 
3.2. Materials and Methods  
 
3.2.1. Rat Basophilic Leukemia cell line (RBL-2H3) 
 
RBL-2H3 were cultured up to about 80% confluence in a humidified 
incubator filled with 5% CO2/95% air at 37°C. The culture medium 
was MEM (Sigma) supplemented with 10% FBS (Sigma) and 1% 
Penicillin/Streptomycin solution (Sigma). 48 hours before the 
experiment, cells were seeded into 96-well plates. The day after, cells 
(7.2 x 104 for each well) were sensitized with an anti-DNP-IgE (0.50 
µg/ml) overnight treatment. After 24 hours, the medicated-medium 
was replaced with DMEM Phenol Free added with BSA (Bovine 
serum albumin; 1 mg/ml, Sigma). When requested by the 
experimental procedure, specific ion channel blockers were pre-
incubated for 20 minutes at 37 °C. Then, different concentrations of 
the given agents (Cromolyn, NaHS, IS-176, L-Cysteine, DADS, sinigrin, 
AITC, HBITC, PhNCS, PhNCO-COOH) were then added (5 min at 37 
°C) each as a triplicate; Cromolyn, a known mast cell membrane 
stabilizer, was used as a reference drug. After the above preliminary 
procedures, cells were challenged with dinitrophenylated human 
serum albumin DNP-HSA (DNP, 10 ng/ml), thapsigargin or 
ionomycin (for 1 h at 37 °C) to induce mast cell degranulation and 
the consequent release of granular contents. The entity of the 
degranulation triggered by these agents, measured in terms of β-
hexosaminidase (β-hex) released, was compared to the maximal 
attainable degranulation (100%) obtained with TRITON-X-100 
(Sigma)(Fig.3). 
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Fig. 3. Representative pictures of RBL-2H3 in normal condition (a), treated with 
triton-X-100 (b) and degranulated with DNP (c).   
 
3.2.2. β-hexosaminidase assay in RBL-2H3 
 
At the end of the experiment, 50 μl of the supernatant from each well 
were mixed with an equal volume of the substrate solution (p-
nitrophenyl-N-acetyl-β-d-glucosaminide 1.4 mM in citrate buffer 0.2 
M, pH 4.5) for 1 h at 37 °C. The reaction was terminated by adding 
100 μl of stopping buffer (Trizma solution 0.3 M , pH 9.4) (Fig. 4). 
The release of β-hex, a reliable marker of mast cell degranulation, 
has been measured by spectrophotometric assays, recording the 
absorbance at 405 nm in a multiplate reader (EnSpire, Perkin 
Elmer). The absorbances  were normalized and the baseline-
corrected values are expressed as a percentage, where the 
degranulation agent (DNP, thapsigargin and ionomycin) represents 
100%. 
 
 
a.RBL-2H3 cells in the 
control well, in which the 
degranulation is not 
challenged. 
b. Effect of Triton-X-
100 (maximal 
release of β-
hexosaminidase). 
c. Granular contents 
released in the 
extracellular 
environment after the 
degranulation triggered 
by DNP. 
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Fig. 4. Scheme of the route of formation of the yellow colored product occurring 
during the β-hex assay. 
 
 
 3.2.3. Statistical analysis 
 
Values are expressed as means ± SEM. One-way ANOVA post test 
Dunnet was used throughout the study to evaluate the significance 
statistically different compare to DNP (or thapsigargin and 
ionomycin). P<0.05 was considered statistically different for *; 
P<0.01 is **; P<0.001 is ***. 
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3.3. Results 
 
The experimental work carried out on RBL-2H3 cell line was based 
on the evaluation of potential inhibitory activities of H2S-donors. The 
release β-hex, as a consequence of mast cell degranulation, was 
measured in RBL-2H3 cells by a spectrophotometric assays. Thus, 
the degree of degranulation was determined in presence of H2S-
donors, which differ in H2S-releasing rates, after inducing 
degranulation by either antigenic or non-antigenic stimuli. 
 
In the first part of the in vitro study, the degranulation of RBL-2H3 
cell line was characterized after the incubation with different stimuli. 
Cells were pre-sensitized with anti-DNP-IgE and then challenged 
with the antigenic stimulus, DNP (10ng/ml, incubated for 1h), that is 
known to promote the activation of FcεRI.  
Concerning the non-antigenic stimuli, cells were triggered by 
ionomycin (1µM) and thapsigargin (1µM), both incubated for 1h. 
Although the final result for those two molecules is to increase the 
intracellular Ca++, they have different mechanisms of action. 
Specifically, ionomycin is a ionophore used to enhance intracellular 
Ca++ levels, by increasing the influx of this ion from the extracellular 
environment. Similarly, thapsigargin raises cytosolic Ca++ 
concentration by inhibiting the SERCA, sarco-endoplasmic reticulum 
Ca++-ATPase, blocking the ability of the cell to pump calcium into the 
sarcoplasmic and endoplasmic reticula. Both antigenic and non-
antigenic stimuli led to an increased intracellular Ca++ concentrations 
and elicited a release of pro-inflammatory mediators and proteases, 
such as the β-hex, from cytosolic vesicles. 
The exposure of RBL-2H3 cell line to Triton-X-100 (incubated for 1h) 
led to a significant release of β-hex, which represents almost the 
totality of the granular content, including proteases and other 
mediators.  
The overnight sensitization process with anti-DNP-IgE (50 µg/ml) 
followed by the exposure to DNP (10 ng/ml) evoked mast cell 
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degranulation. The amount of the β-hex released was 50.5±8,3 % of 
the one induced by Triton-X-100.  
Regarding the degranulation independent from the receptor FcεRI  
but induced by Ca++ mobilization, the release of the β-hex was 
63.6±1,7 % when thapsigargin 1 μM was incubated for 1h and  
69±2,7 % with ionomycin 1 μM, incubated for 1h. (Graph. 1). The 
basal level of β-hex release (vehicle) is 7.2±0,5 %. 
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Graph. 1. Antigenic and non-antigenic degranulation stimuli. Incubation for 1h of 
RBL-2H3 with Triton-X-100 led to a maximum release of β-hex (100%). DNP, 
thapsigargin and ionomycin degranulate cells as well and resulted statistically 
different compared to Triton-X-100. Bars are means ± SEM. **, P<0.01 vs Triton-X-
100. 
 
Disodium cromoglycate (Cromolyn) has been used extensively as an 
anti-allergic drug, and a study has illustrated that it may indirectly 
prevent the influx of Ca++ by blocking the Cl- channels[190]. It has been 
used at the concentration of 1 mM, concentration that showed a good 
mast cell stabilization, thus capacity to reduce mast cell activation. It 
was incubated after the overnight sensitization step and then the 
degranulation was stimulated by the antigen. DNP evoked β-hex 
release in the treated cells in a percentage equal to 50.9±9.7%, 
compared to the β-hex released by the cells treated solely with the 
antigen. Since no previous papers were published with the effect of 
H2S on RBL-2H3, a proper concentration-curve response was 
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necessary. The fast H2S-donors, NaHS (10, 100, 1000 µM) was pre-
incubated for 5 min and then DNP was added to the cells. NaHS 
inhibited in a concentration-dependent manner the DNP-induced 
mast cell activation (Graph. 2a and 2b), with a pIC50 value of 
3.44±0,04. 
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Graph. 2a    Graph. 2b 
Graph. 2a. NaHS inhibits RBL-2H3 degranulation induced by DNP. Bars represent 
the release of β-hex, expressed in percentage, induced by DNP 10 ng/ml (100%) in 
presence of the drugs (Cromolyn and NaHS). Bars are means ± SEM. *,P<0.05, 
***,P<0.001 vs DNP. Graph 2b. Logarithmic dose-response curve of the inhibitory 
effects of NaHS toward DNP-induced degranulation. pIC50 value corresponds to 
3.44±0.04 
NaHS was also tested in presence of antigen-independent 
degranulation: thapsigargin and ionomycin. As shown in the Graph. 
3 , NaHS did not inhibit mast cell activation, suggesting that its 
inhibitory activity might not be related to the Ca++ fluxes and/or ion 
channels involved in the degranulation, but rather related to the 
interaction with the FcεRI receptor. 
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Graph. 3 Thapsigargin- and ionomycin-induced degranulation. NaHS did not 
antagonize the degranulation induced by one hour of incubation with thapsigargin 
and ionomycin in RBL-2H3 cells. Bars, expressed in percentage, are means ±SEM of 
the β-hex released. 
Further experiments were carried out with IS-176, (100, 300, 1000 
µM) a p-hydroxybenzo-thioamide behaving as a slow H2S-donor. IS-
176 caused a concentration-related significant inhibition of the 
release of β-hex (Graph. 4a), with a pIC50 value of 3,27±0,01 as 
represented in Graph. 4b. 
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             Graph. 4a      Graph. 4b 
Graph. 4a. IS-176 inhibits RBL-2H3 degranulation DNP-induced. Bars represent 
the release of β-hex induced by DNP 10 ng/ml (100%) in presence of drugs 
(Cromolyn, NaHS and IS-176). Bars are means ± SEM. ***,P<0.001 vs DNP. Graph 
4b. Dose-response curve of the inhibitory effects of IS-176 toward DNP-induced 
degranulation. pIC50 value corresponds to 3,27 ±0,01 
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So far, it is reported in the literature that among various specific 
mechanism of action, H2S seems to activate the KATP and the Kv7 
potassium channels[60]. For this purpose, specific blockers of KATP 
and Kv7 channels were used. Glibenclamide and XE991 (both 10 µM) 
respectively, were tested in order to evaluate their potential 
involvement in the inhibition of mast cell degranulation. 
Since NaHS and IS176 (1mM) showed a good inhibition in the 
degranulation process, they were both used as reference drugs in 
further experiments. 
The results showed that both potassium channel blockers did not 
antagonize the inhibitory effects of the H2S-donors, but both 
synergized with H2S (Graph. 5) reducing the amount of the β-hex 
released. NaHS (1 mM) in the presence of glibenclamide and XE991 
induced a degranulation equal to 15.07±0.58% and 17.50±7.35%, 
respectively, while IS-176 (1 mM) in presence of glibenclamide and 
XE991 degranulates with values equal to 17.82±1.15% and 
5.89±2.73%, respectively. 
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Graph. 5. Potassium channel blockers synergize NaHS and IS-176. Bars represent 
the β-hex released during degranulation induced by DNP 10 ng/ml (100%) in 
presence of the drugs (NaHS and IS-176) combined or not with potassium channel 
blockers (glibenclamide and XE991). Bars are means ± SEM. ***, P<0.001 vs DNP. 
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Lately, focusing on the likelihood that H2S may be an important 
physiological factor during degranulation, I tested the production of 
endogenous H2S in RBL-2H3 cells. Increasing concentrations of 
exogenous substrate of CSE, L-cysteine (0.3, 1, 3, 10 mM) were added 
to the cells, in the presence of the antigen, DNP 10 ng/ml. The results 
suggested that RBL-2H3 cells produce H2S in an endogenous way, 
supporting its role as mediator of the inflammatory signaling. 
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Graph. 6. RBL-2H3 cells endogenously produce H2S in degranulation DNP-
induced. Bars represent the release of β-hex induced by DNP 10 ng/ml (100%) 
expressed in percentage in presence of the drugs (Cromolyn, NaHS and IS-176) 
and in presence of an exogenous administration of L-cysteine. Bars are mean ± 
SEM. ***,P<0.001 vs DNP. 
In this second part of my study, experimental work has been focused 
on natural compounds. Different molecules belonging to the 
Brassicaceae and Alliaceae family were tested. After screening an 
array of natural compound by amperometric approach, the selected 
compound were tested on RBL-2H3 cell line in order to determine a 
feasible inhibitory effect on the degranulation process. 
DADS is a major organosulfur compound found in garlic. Its activity 
was tested in RBL-2H3 after inducing basophil activation with DNP 
(10 ng/ml). The results showed that DADS inhibited degranulation 
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only at the maximal concentration tested (1mM) and not when lower 
concentrations of the polisulfide (10, 30, 100, 300 µM) were used. 
The amount of β-hex released from the granular content using DADS 
1 mM (51.94±10.38%) resulted statistically different  towards the 
one released by using DNP (100%) 
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Graph. 7. Inhibitory effects of DADS on the DNP-induced degranulation in RBL-
2H3 cells. Bars represent the percentage of the β-hex released after the treatment 
with each compound in respect of DNP-induced degranulation (100%). Each data 
value is expressed as mean ± SEM. **, P < 0.01; ***, P<0.001 vs DNP.  
Sinigrin, the glucoside belonging to the Brassicaceae family, 
abundant in Sinapis Nigra, was tested at different concentrations (1-
1000 μM). The response elicited with each dose of drugs is described 
in terms of β-hex released and exhibits a defined all-or-none effect. 
Indeed, only the 1 mM concentration of sinigrin showed a strong 
inhibitory activity of the DNP-induced degranulation (24.32±2.77%). 
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Graph. 8. Inhibitory effects of sinigrin on the DNP-induced degranulation in RBL-
2H3 cells. Bars represent the percentage of the β-hex released after the treatment 
with each compound in respect of DNP-induced degranulation (100%). Each data 
value is expressed as mean ± SEM.   *** P < 0,001 vs DNP.  
Notably, the enzymatic decomposition of sinigrin leads to the 
formation of allyl isothiocyanate (AITC), glucose and sulfate ions. 
The aglicone AITC (10-1000 μM) was incubated in RBL-2H3 5 min 
before the DNP-induced degranulation. The results showed a full 
abolition of mast cell activation in a clear concentration-dependent 
manner. Inhibitory effects are exhibited even at very low 
concentration, demonstrated by the low percentage of β-hex release 
compare to DNP (AITC 10 µM, 26.85±13.67; AITC 30 µM, 
5.88±4.58%; AITC 100 µM, -1.35±0.96%; AITC 300 µM, 
0.53±2.135%; AITC 1 mM, 1.14±2.1%). 
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Graph. 9. Inhibitory effects of AITC on the DNP-induced degranulation in RBL-2H3 
cells. Bars represent the β-hex release induced by DNP 10 ng/ml (100%) in 
presence of the drugs (Cromolyn, NaHS, IS-176 and AITC). Each data value is 
expressed as mean ± SEM. ***, P<0.001 vs DNP. 
Among ITCs, the hydrolysis of sinalbin, the glucoside extracted by 
Sinapis Alba, leads to the formation of HBITC. Once added to cells 
(10, 30, 100, 300 μM and 1 mM), it provoked the inhibition of the β-
hex release DNP-induced in a clear concentration-dependent fashion, 
with an pIC50 value of 3.80 (±0.1) (Graph 10). 
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Graph. 10. Inhibitory effects of HBITC in DNP-induced degranulation in RBL-2H3 
cells. Bars represent the percentage of the β-hex released after the treatment with  
Cromolyn, NaHS, IS-176 and HBITC in respect of DNP-induced degranulation 
(100%). Each data value is expressed as mean ± SEM. ***. P<0.001. 
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Other synthetic ITCs were tested and the results were very similar. 
In particular PhNCS fully abolished the β-hex release with a clear 
concentration-dependent manner (Graph 11). The inhibitory 
activity is shown even at low concentration, in particular the total 
suppression of β-hex release is elicited at 100 µM of PhNCS (β-hex 
percentage = 2.8±1.50%). 
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Graph. 11. Inhibitory effects of PhNCS on the DNP-induced degranulation in RBL-
2H3 cells. Bars represent the β-hex release induced by DNP 10 ng/ml (100%) in 
presence of the drugs (Cromolyn, NaHS, IS-176 and PhNCS). Each data value is 
expressed as mean ± SEM. **, P<0.01; ***, P<0.001 vs DNP. 
 
PhCNS-COOH, a synthetic isothiocyanate, showed a clear dose-
response in inhibiting the basophilic activation (Graph 12). 
Specifically, it reduces the β-hex release even with a higher potency 
than the analogue compound without the carboxyl group. 
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Graph 12. . Inhibitory effects of PhNCS -COOH on the DNP-induced degranulation 
in RBL-2H3 cells. Bars represent the β-hex release induced by DNP 10 ng/ml 
(100%) in presence of the drugs (Cromolyn, NaHS, IS-176 and PhNCS-COOH). Each 
data value is expressed as mean ± SEM. *, P<0.05; **, P<0.01 and ***, P<0.001 vs 
DNP. 
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3.4. Discussion 
 
Degranulation in the RBL-2H3 cell line was induced using different 
mechanisms that ultimately ended in increased intracellular Ca++ 
levels and thus degranulation, with release of β-hex from granules. 
The maximal release of granular contents was ensured by Triton-X-
100 (100% of degranulation). After 1 h of incubation with DNP,  cells 
exhibited 50.5% of the maximal degranulation. Nevertheless, the 
mobilization of intracellular Ca++ (thapsigargin) and external flux of 
Ca++ (ionomycin) also evoked a significant degranulating response, 
(63% and 69%, respectively), confirming the importance of Ca++ in 
mediator release.  
Cromolyn was used as positive control in DNP-induced 
degranulation, since it showed an inhibition of basophils activation 
(about 50% of inhibition compare to DNP, 100%). Similarly, NaHS 
elicited significant properties in inhibiting DNP-induced 
degranulation in a clear concentration-dependent fashion. The 
activity was comparable to the effects of Cromolyn at a 1 mM 
concentration. This result initially suggests a potential involvement 
of NaHS in the FcεRI pathway. 
In order to understand the source of the inhibitory effect of NaHS in 
this process, thapsigargin and ionomycin were also tested in 
presence of the salt. Interestingly, NaHS did not antagonize mast cell 
activation induced by Ca++ mobilization. The lack of activity with this 
type of degranulation suggested that its effect is related to FcεRI 
binding or to downstream signaling, rather than the increase in 
intracellular calcium.  
As previously highlighted, the problem of NaHS as H2S-donor is the 
rapid release and the low levels of H2S in the biological environment. 
Thus, the p-hydroxybenzothioamide IS-176, a slower H2S-donor, was 
selected and it showed a stronger inhibition of RBL-2H3 
degranulation (28.99±2.37%) than the equimolar concentration of 
NaHS  (43.41±4.22%). The stronger efficacy could be explained by 
the difference in H2S-releasing rate. The hypothesis is that the effect 
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of H2S in experimental systems may be dependent upon the manner 
in which cells and tissues are exposed to H2S. 
To corroborate the previous data, further experiments highlighted 
the potential involvement of other K+ channels. Precisely, it is 
established that H2S has activity on KATP and Kv7 potassium channels 
in vascular smooth muscle cells, inducing hyperpolarization and 
vasorelaxing effects. In this set of experiments we tested weather or 
not H2S might act on potassium channels. Particularly, glibenclamide 
and XE991 were used to validate the type(s) of K+ channel that may 
be present and the potential effects due to H2S. In contrast to 
excitable cells, mast cell membrane hyperpolarization is required to 
support Ca++ entry[150]. Potassium channel activation may be even 
more critical than the entry of Ca++ in the control of mediator release. 
Therefore, drugs that specifically enhance the opening probability of 
K+ channels, such as potassium channel openers (KCOs), could affect 
the process of mast cell degranulation. It may be hypothesized that 
KATP and Kv7 blockers, by preventing the K+ efflux in the extracellular 
environment, promoted a membrane depolarization, reducing the 
driving force for Ca++ and degranulation. Indeed, the H2S-donors did 
not antagonize the depolarizing effect of both potassium channel 
blockers, but they synergized in inhibiting mast cell activation. This 
results excluded an hyperpolarization due to H2S, indicating that 
KATP and Kv7 channels activation is not involved in its mechanism of 
action in RBL-2H3 cells. 
L-cysteine, an endogenous substrate for the production of H2S, 
inhibited the antigen-induced degranulation of RBL-2H3 cells, 
suggesting that an endogenous production of H2S might be a 
physiological regulatory mechanism and also a useful strategy when 
mast cells degranulate. 
The polysulfide DADS showed only slight efficacy in inhibiting the 
granular contents release from RBL-2H3 at the highest tested 
concentration, 1 mM. Thus, other molecules of natural origin were 
studied. The organosulfur molecules showed a promising inhibitory 
profile towards the DNP-induced degranulation. All the ITCs, 
inhibited the β-hex release in a clear concentration-dependent 
manner. In particular, AITC and PhITC completely abolished the 
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degranulation at the concentration of 100 µM, suggesting that the 
presence of the isothiocyanate group is pivotal for the beneficial 
effects of these compounds. Ultimately, PhNCS-COOH, which is not a 
natural molecule, but maintains the isothiocyanate moiety and a 
similar chemical structure, resulted more effective in abolishing 
degranulation beginning at 10 µM. The presence of a carboxyl group 
allowed an increased efficacy likely due to the improvement of H2S-
releasing properties wen endogenous thiols are present. Moreover, 
the carboxyl group is also a good exploitable group from a medicinal 
chemistry point of view, that can be used to develop other 
derivatives. 
  
3.5. Conclusions 
 
Concluding, RBL-2H3 cells (i.e., the rat basophilic leukemia cell line) 
are a widely used model of mast cells, which are critical effector cells 
in inflammation. This experimental work demonstrated that  H2S is 
an important mediator in the inhibition of antigen-induced 
degranulation of RBL-2H3, indicating a possible innovative strategy 
for the treatment  of allergic/inflammatory diseases and stressing 
the necessity to test this hypothesis on other cell lines, more closely 
resembling mast cell behavior.   
79 
 
Chapter 4 
 
Effects of H2S-donors on mast 
cell degranulation 
 
4.1.  H2S inhibits mast cell renin release 
 
The mast cell-like cell line RBL-2H3 is not universally considered an 
optimal model of native mast cells. Therefore, the characterization of 
the activity of H2S-donors on the degranulation of authentic mast cell 
was a necessary step in the evaluation of potential therapeutic 
effects and translational applications in mast cell-derived diseases. 
For this purpose, PhNCS-COOH was selected as representative 
compound, on the bases of the previous experiments. 
Therefore, PhNCS-COOH has been evaluated in original mast cells (of 
human and murine origin), degranulated by antigenic and non-
antigenic stimuli. The same kind of experiments carried out on RBL-
2H3 and other different types were performed in order to investigate 
the feasibility of the three cell lines. Here below there is a detailed 
description of the human and murine mast cells that have been used 
in this PhD thesis. 
Finally, β-hex and renin were used as marker of degranulation and 
measured after challenging the cells with DNP, Thapsigargin, 
ionomycin and ATP. 
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4.1.1. Human mastocytoma cell line (HMC-1) 
 
A particular problem of human mast-cell research is the difficulty in 
obtaining human cells material for in vitro studies. HMC-1 is one of 
the currently available human mast cell line. 
HMC-1 cells were found to express several mast cell-related markers, 
even though their expression is low. In contrast, HMC-1 cells display 
a high expression of histamine and c-Kit, the receptor for stem-cell 
factor. The majority of the cells were stained with a monoclonal 
antibody (MoAb) against the mast cell-specific serine protease 
tryptase. Of particular interest was the finding that the level of 
tryptases was reduced, when compared with other mast cells and 
that beta-tryptase mRNA, but not alpha-tryptase mRNA, was 
expressed in HMC-1[191]. Both heparin and chondroitin sulfate were 
found to be present in approximately equal amounts. HMC-1 lack 
surface expression of the high-affinity IgE receptor, which was 
confirmed by the absence of mRNA of the alpha- and beta-chains of 
the IgE-receptor complex. However, a strong expression of the 
gamma-chain of the IgE-receptor complex was detected[192]. Also 
HMC-1 cells express renin protein. Therefore, in HMC-1 were 
evaluated the expression of renin mRNA and renin protein. Western 
analysis of HMC-1 homogenate, probed with the anti-renin Ab, 
showed a band for renin around 42-kDa (Fig 18). 
 
 
Fig. 18. Western blot probing rat kidney homogenate (20 µg per lane) and HMC-1 
cells (50 µg per lane) for renin with the polyclonal anti-renin Ab[175]. 
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4.1.2. Bone marrow-derived mast cells 
 
Mast cells are challenging cells to obtain for experimental studies. 
There are many procedures and different types of isolations that 
lead to mast cells in vitro. For example, murine peritoneal mast cells 
have been widely used, as a single peritoneal lavage yields large 
numbers of mast cells that can be easily purified[193]. However, this 
mast cell subtype might not mimic human mast cells, since human 
peritoneal cavity is free of mast cells. Techniques for generating mast 
cells from progenitor cells such as bone-marrow or blood-derived 
mast cells are preferred. Morphological and functional properties 
such as the expression of FcεRI are assumed to be related to mature 
status[194]. Such cell cultures generally produce homogeneous mast 
cell-like populations, even if the culture time is long and expensive. 
The type of mast cells used in these studies derives from the 
isolation of murine bone marrow cells and their differentiation in 
mature mast cells. The differentiation into typical mast cells occurs 
within 4-5 weeks with the help of differentiation factors, such as SCF 
and IL-3. Maturation was confirmed by classical Toluidine-Blue 
granular staining, which demonstrated a double-positive result 
(>90%) for the FcεRI and c-Kit receptors, and the renin protein 
measurement (Fig. 19). Notably, renin protein was present in bone 
marrow cells at the time of their isolation and continued to be 
present during the differentiation phase (Fig. 19).   
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Fig 19. Granular staining and expression of c-Kit, FcεRI, and renin in BMMCs. A: 
Characteristic Toluidine Blue stained murine bone marrow cells at isolation and 
differentiated BMMCs after 5 weeks in culture with IL-3 and SCF. B. Representative 
Western blots with anti-mouse renin antibody show a renin-positive band in total 
protein lysate (50 mg/lane) of BMMCs (5-week culture) and KNRK rat kidney cells 
used as positive control[195]. 
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4.2. Material and methods 
 
4.2.1. Human Mastocytoma Cell line (HMC-1) 
 
HMC-1 cells were kindly provided by Dr. J. H. Butterfield (Mayo 
Clinic, Rochester, MN). Cells were maintained in suspension culture 
as previously described[174]. Briefly HMC-1 cells were maintained in 
suspension culture at high density in Iscove’s modified Dulbecco’s 
medium (HyClone) supplemented with 10% of heat inactivated FBS 
(HyClone) and 1.2 mmol/L monothioglycerol and kept at 37°C, 5% 
CO2. Then, 2 or 3 pooled confluent flasks were pelleted and cells 
washed twice with Ringer buffer (pH 7.4). Pelleted HMC-1 were then 
resuspended in Ringer buffer and equal volumes of cell suspension 
were aliquoted in Eppendorf tubes and incubated at  
with the given agents (i.e. NaHS or 4-COOH-ITC) for 5 min. By 
inhibiting the endoplasmic reticulum Ca++ pump, thapsigargin blocks 
reuptake of stored Ca++ ions, thereby preventing cyclical release or 
partial release and refilling of internal Ca++ stores. 
The calcium ionophore A23187 instead mimics the Ca++ ions, 
enhancing the cytoplasmic levels of Ca++. 
Thus, A23187, Thapsigargin or ATP were subsequently added to the 
incubation mixture for 20 minutes at 37° C. At the end of protocol, 
samples were transferred to ice and then centrifuged at 1000 g for 
10 min. Supernatants were collected and kept in ice until β-
hexosaminidase (β-hex) and renin release was evaluated. The 
remaining cell pellets were lysed with Cell Lysis Buffer 0.5 X 
(purchased by Cells Signaling) and centrifuged at 13,000 g. 
Supernatants were then used for protein and total β-hex content 
determination. All results were normalized and expressed as percent 
above control. 
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4.2.2. Isolation and differentiation of mast cell from 
murine bone marrow.  
 
BMMC were obtained by C57BL/6 WT mice that were anesthetized 
with CO2 vapor and killed by cervical dislocation as approved by the 
Weill Cornell Medical College Institutional Animal Care and Use 
Committee. Bone marrow was flushed out from femurs and tibia. 
Bone marrow-derived cells were cultured in RPMI-1640 medium 
(Invitrogen Life Technologies, Carlsbad, CA) containing antibiotics 
(10 U/ml penicillin/streptomycin), 10% heat-inactivated fetal calf 
serum, 2-β-mercaptoethanol (55 μmol/L), recombinant murine 
interleukin-3 (IL-3) and stem cell factor (SCF) (both 20 ng/ml; 
PeproTech, Rocky Hill, NJ). Bone marrow-derived cells were cultured 
at a density of 0.5 x 106 cells/ml. Cell medium was changed every 3-4 
days and non-adherent cells were transferred to a new culture flask. 
Mature BMMCs were obtained after 4-5 weeks when >90% of cells 
were double positive for c-kit/CD117 and high-affinity IgE receptor 
(FcεRI). All experiments were performed with BMMCs cultured for 4 
to 7 weeks. When cells were degranulated by the antigen DNP, they 
were previously sensitized for 16 hours with 0.125 mg/mL anti-DNP 
IgE (Sigma-Aldrich), 1 x 105 BMMCs per sample were washed and 
resuspended in Ringer’s buffer (pH 7.4). Equal cell volumes were 
aliquoted in 96 wells and challenged with 10 ng/mL antigen DNP for 
20 min at 37 °C in the absence or presence of NaHS 1 mM and 
PhNCS-COOH (10-300 µM, 5 min at 37 °C). When other mast cells 
activators were used no cells sensitization was needed. After a pre-
incubation for 5 min with PhNCS-COOH, cells were incubated with 1 
µM A23187 calciumionophore, 300 µM ATP and 300 nM thapsigargin 
(all from Sigma-Aldrich) for 20minutes at 37 °C. Unlike A23187, that 
was known to degranulate BMMCs at the concentration of 1 µM, 
thapsigargin needed a concentration curve response in order to 
compare the degranulation elicited by A23187. The selected 
concentration was 300 nM.  
At the end of the incubation, samples were placed on ice and 
centrifuged at 400g for 5 min. Supernatants were collected and used 
to measure the β-hex release. Cell pellets were lysed with 0.5% 
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Triton X-100, and total lysates were used to determine total β-hex 
content. 
 
4.2.3. β-hexosaminidase assay in HMC-1 and BMMC 
 
After the sensitization with the given agents, the supernatants were 
collected. 20 μl of supernatants from each sample were placed into a 
96 well plate each as a triplicate and 50 μl of the β-hex substrate (p-
nitrophenyl-N-acetyl-β-d-glucosaminide 1.3 mg/ml dissolved in 
citrate buffer 0.1 M, pH 4.5)  was added and incubated for 90 min at 
37° C. The reaction was stopped with 200 μl of glycine (0.2M pH 
10.7). Optical density was read at 405 nm on a spectrophotometric 
plate reader using SoftMax Pro version 4.8 (Molecular Devices, 
Sunnyvale,CA). For BMMC cells, β-hex release was expressed as the 
percentage ratio between supernatant and total β-hex (where total 
β-hex is equal to the sum of β-hex content in supernatant and total 
lysate). For HMC-1 cells, the value of β-hex is expressed as the 
percentage of β-hex release above the control (basal levels). 
 
4.2.4. Renin assay in HMC-1 cells 
 
For the renin assay, samples (500µl of each supernatant) were 
incubated for 1.5 h at 37° C with 0.1 mg/ml human angiotensinogen 
(AnaSpec) and then renin activity (measured in terms of angiotensin 
I formed) was determined by GammaCoat Plasma Renin Activity 125I 
Radioimmunoassay (DiaSorin, Stillwater, MN). The detection limit 
was approximately 0.01 pmol. 
 
4.2.5. Renin assay in BMMC cells  
 
Renin activity was measured in supernatants from BMMCs (treated 
with the given agents) using a GammaCoat Plasma Renin Activity 125I 
Radioimmunoassay kit (DiaSorin, Stillwater, MN) according to the 
manufacturer’s instructions. Briefly, BMMCs supernatants were 
diluted 1:500 in Ringer buffer and incubated with porcine 
angiotensinogen substrate (Sigma-Aldrich), maleate buffer and PMSF 
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(part of the DiaSorin kit). The reaction for angiotensin I production 
was conducted for 1.5 hours at 37° C. Total protein concentration 
was measured using a DC protein assay kit (Bio-Rad Laboratories, 
Hercules, CA). Results were normalized to total protein. The 
detection limit was approximately 0.01 pmol. 
 
4.2.6. Statistical Analysis 
 
Values are expressed as means ± SEM. Unpaired t-test was used 
throughout the study. P<0.05 was considered statistically significant. 
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4.3. Results  
 4.3.1. BMMCs 
The isothiocyanate PhNCS-COOH, that had emerged as the most 
suitable H2S-donor of the series, was tested in murine mast cells 
(BMMC) after the exposure to canonical degranulating agents 
(calcium ionophore A23187, Thapsigargin, DNP and ATP).  
BMMCs were previously sensitized for 16 hours with anti-DNP-IgE 
0.125 µg/ml and then challenged with DNP 10 ng/ml, for 20 min, to 
induce degranulation. The  degranulation due to DNP (4.37 ± 0.53 % 
of β-hex released; Mean ± SEM), statistically different from the non-
treated cells (2.07 ± 0.31 % of β-hex released), was inhibited in a 
concentration-dependent manner by PhNCS-COOH. In fact, according 
to the results previously recorded in RBL-2H3 cells, this H2S-donor 
was able to reduce mast cell activation and their subsequent release 
of β-hex. In particular, 100 and 300 µM concentrations completely 
restored basal levels of β-hex (1.97 ± 0.24 %; 1.65 ± 0.20 %, 
respectively) (Graph 1a). 
Alongside the release of β-hex as a marker of degranulation, mast 
cell-derived renin release was also evaluated. BMMC-released renin 
was enzymatically active, because it formed angiotensin I from 
angiotensinogen (added as an exogenous substrate). After 
sensitization of BMMCs with murine anti-DNP-IgE, challenge with 
DNP also caused release of renin (approximately 1.5 fold increase 
above the control), measured as renin activity and expressed as an 
increase in angiotensin I forming activity. When the H2S-donor 
PhNCS-COOH was added in presence of DNP, a reduction of renin 
activity was observed in a concentration-dependent manner. Only 
the highest concentration of PhNCS-COOH restored the basal levels 
and resulted statistically significant with a P value of 0.02 (Graph 
1b).  
Concerning the non-antigenic stimuli, the degranulation elicited by 
modulating Ca++ influx was induced by a calcium ionophore, A23187 
(1µM) and thapsigargin (300nM), both incubated for 20 min (Graph 
3). A23187 1 µM degranulated BMMCs and induced a β-hex release 
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(~12%) when incubated alone. In the presence of PhNCS-COOH (10-
300µM) β-hex release was inhibited in a concentration-manner, until 
complete abolition of the effect of the calcium ionophore. Similar to 
isothiocyanate, NaHS (1mM) also elicited a strong inhibition of β-
hex,  comparable to basal level (2.59 ± 0.22 %)(Graph 2a). Likewise, 
renin release was enhanced by the exogenous administration of 
A23187 1 µM, and a concentration-dependent inhibition of its 
release was elicited by PhNCS-COOH (Graph 2b). NaHS 1 mM also 
markedly inhibited renin release (Graph 2b). 
Moreover, the possible role of intracellular Ca++ release was 
examined by depleting internal Ca++ stores with thapsigargin. The 
degranulation induced by thapsigargin 300 nM was largely inhibited 
even by low concentrations of the H2S-donor PhNCS-COOH (10-300 
µM). Similarly, NaHS 1mM restored the basal levels of β-hex (1.55 ± 
0.23 %) when thapsigargin-induced degranulation occurred (Graph 
4). 
Ultimately, ATP was used to induce degranulation and thus, β-hex 
release. A statistically significant degranulation was observed after 
incubating BMMCs with ATP 300 µM, with β-hex levels of 5.43 ± 0.56 
%. Also in this type of mast cell activation, PhNCS-COOH displayed a 
dose-dependent inhibitory effect, with a maximal inhibition of the 
degranulation at the highest concentration (300 µM). Nevertheless, 
NaHS 1 mM did not significantly reduced ATP-induced β-hex release 
(4.06 ± 0.69 %) (Graph 5a). 
Released renin was enzymatically active. It was expressed as an 
increase in angiotensin I-forming activity. When BMMCs were 
treated with ATP 300 µM, a significant increase in renin activity 
occurred above control levels. PhNCS-COOH inhibited renin release, 
albeit with no concentration-dependence. NaHS 1 mM did not 
showed inhibitory effects on renin release (Graph 5b). 
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  Graph 1a    Graph 1b 
Graph 1. DNP elicits degranulation and renin release in BMMC cells: inhibition by 
H2S-donors. 1a) Incubation of BMMC cells with DNP 10 ng/ml, 20 min, elicits 
degranulation in BMMC cells. β-hex and renin release were inhibited by PhNCS-
COOH (10-300 μM) in a concentration dependent manner. 1b) Renin activity as 
affected DNP 10 ng/ml was measured in BMMC supernatant in terms of 
angiotensin I (Ang I) formation (µg/hour per mg of total protein). Data are 
expressed as means ± SEM. *, P<0.05; **, P<0.01; ***, P<0.001 vs DNP 10 ng/ml by 
unpaired t-test. 
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Graph 2a    Graph 2b 
Graph 2. A23187 elicits degranulation and renin release in BMMC cells: inhibition 
by H2S-donors. 2a) The degranulation induced by A23187 1μM, incubated for  20 
min in BMMC, was inhibited by NaHS 1 mM and PhNCS-COOH (10-300 μM), which 
evoked a dose-response efffect. 2b) Renin activity increased when A23187 1μM is 
incubated in BMMC for 20 min. It is expressed in terms of angiotensin I (Ang I) 
formation (µg/hour per mg of total protein) and its activity was significantly 
reduced in the presence of the H2S-donors. Bars are mean ± SEM of the percentage 
of β-hex release. **, P<0.01; ***, P<0.001 vs A23187 1µM by unpaired t-test. 
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Graph 3. Thapsigargin elicits degranulation in BMMC cells. 
Dose-response curve of the effect of thapsigargin (10-1000 nM) after 20 min of 
incubation in BMMC cells. The bar graph represent the degranulation of BMMC 
expressed in percentage of β-hex released Points are mean ± SEM of the 
percentage of β-hex release.  
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Graph 4. Thapsigargin elicits degranulation and renin release in BMMC cells: 
inhibition by H2S-donors. Dose-response inhibitory effects of the given agents, 
NaHS 1 mM and PhNCS-COOH (10-300 μM), when BMMC cells were incubated 
with thapsigargin 300 nM, 20 min. Bars are mean ± SEM of the percentage of β-hex 
release. ***, P<0.001 vs thapsigargin 300 nM by unpaired t-test. 
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Graph 5a    Graph 5b 
 
Graph 5. ATP elicits degranulation and renin release in BMMC cells: inhibition by 
H2S-donors. 5a)Dose-response inhibitory effects of the given agents, NaHS 1 mM 
and PhNCS-COOH (10-300 μM), when BMMC cells were incubated with ATP 300 
µM, 20 min. 5b) Renin activity as affected ATP 300µM was measured in BMMC 
supernatants in terms of angiotensin I (Ang I) formation (µg/hour per mg of total 
protein). Bars are mean ± SEM. **, P<0.01; ***, P<0.001 vs ATP 300 µM by unpaired 
t-test. 
 
4.3.2. HMC-1 cells 
Similar to BMMCs, HMC-1 cells were also degranulated by 
thapsigargin (1 µM), calcium ionophore A23187 (10 µM) and ATP 
(100 µM). 
A characterization of the PhNCS-COOH effect in human mast cell 
activation was done by modulating Ca++ influxes, by challenging 
HMC-1 with A23187 (10µM) and thapsigargin (1 µM), both 
incubated for 20 min at 37° C.  
A23187 10 µM degranulated HMC-1 and induced β-hex release when 
incubated alone. In the presence of PhNCS-COOH (10-300µM) β-hex 
release was inhibited in a concentration-dependent manner. The 
entity of the inhibition was remarkable when the 300 µM of the 
isothiocyanate was added, leading to an abolition of the effect of the 
calcium ionophore. Basal level of β-hex (control), that was used to 
calculate the % of β-hex increase, is 1.81 ± 0.12 % (Graph 6). 
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Similarly, thapsigargin 1 µM led to a β-hex release ~35 % 
(percentage of β-hex released above the control). The effect on 
degranulation induced by the SERCA pump inhibitor was drastically 
inhibited only by higher concentrations of the H2S-donor, PhNCS-
COOH 300 µM (full abolishment of the β-hex release). Thapsigargin-
induced renin release, measured in terms of renin activity, was 
inhibited by PhNCS-COOH. In particular, the isothiocyanate added at 
300 µM almost completely abrogated renin release (~1.7% of renin 
protein release above the control) (Graph 7). 
Ultimately, ATP-induced degranulation and the related renin release 
were evaluated. It was observed a statistically difference  β-hex 
release after incubating HMC-1 with ATP 100 µM (~40% of 
degranulation). PhNCS-COOH showed an inhibitory effect, but not in 
a dose-dependent fashion in the ATP-induced degranulation. Indeed, 
only PhNCS-COOH 100 and 300 µM resulted efficient the in reducing 
β-hex release (Graph 8a). Moreover, when HMC-1 were treated with 
ATP 100 µM, a significant increase in renin activity was measured, 
expressed as Ang I formed. ATP-induced renin release was only 
inhibited by PhNCS-COOH 100 and 300 µM(Graph 8b). 
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Graph 6. A23187 elicits degranulation and renin release in HMC-1: inhibition by 
PhNCS-COOH. Concentration-response curves for the degranulating (i.e., β-hex 
release) and renin-releasing effects of A23187 10 µM (20 min incubation), alone or 
in the presence PhNCS-COOH (10-300 µM). Bars are means ± SEM. *P , 0.05, **P , 
0.01 vs A23187 by unpaired t-test. 
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Graph 7. Thapsigargin elicits degranulation and renin release in HMC-1 cells: 
inhibition by PhNCS-COOH. 7a)Inhibitory effects of PhNCS-COOH (10-300 μM), 
when HMC-1 cells were incubated with ATP 100 µM, 20 min. 7b) Renin activity as 
affected thapsigargin 1µM was measured in HMC-1 supernatant in terms of 
angiotensin I (Ang I) formation (% of renin released above the control). Bars are 
mean ± SEM. 
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Graph 8. ATP elicits degranulation and renin release in HMC-1 cells: inhibition by 
4-COOH-ITC. 8a)Incubation of HMC-1 cells with ATP 100 μM, 20 min, elicit 
degranulation and renin release, inhibited by 4-COOH-ITC (10-300 μM). Bars are 
mean ± SEM.  of the percentage of β-hex and renin above ATP (100%). β-hex and 
renin release are expressed as percentage above the control. Bars are means ± 
SEM. *P , 0.05, **P , 0.01; ***, P<0.001 vs ATP by unpaired t-test.  
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4.4. Discussion 
The experimental results of this part of the study show that H2S 
released from H2S-donor modulates mast cell activation.  
Particularly, HMC-1 cells and BMMC cells were used to test PhNCS-
COOH, an isothiocyanate capable of releasing H2S with a slow and 
long-lasting kinetic. In addition to β-hex, another recent marker was 
evaluated from activated mature mast cells: renin protein. 
It was demonstrated that PhNCS-COOH inhibited mast cell 
degranulation as well as renin release.  
 
4.4.1. BMMC cells 
 
The stimulation of BMMC by cross-linking of FcεRI was achieved by 
using the antigen, DNP (10 ng/ml). After 20 min of incubation it 
elicited mast cell degranulation and also the release of enzymatically 
active renin protein.  
PhNCS-COOH inhibited in a clear concentration-manner both 
mediators release (β-hex and renin), confirming a potential 
interaction with the high affinity IgE receptor or the downstream 
signals (Graph 1). Moreover, the inhibitory activity towards mast 
cell activation and subsequent renin release was also elicited by 
NaHS.  
Calcium ionophore (A23187) and thapsigargin were exogenously 
administered at different concentrations (1 µM and 300 nM, 
respectively) in order to obtain a comparable degree of 
degranulation. The two ion flux modulators led to a final increased 
intracellular Ca++ concentrations and a final release of pro-
inflammatory mediators and β-hex, from cytosolic vesicles. 
PhNCS-COOH and NaHS inhibited the degranulation and renin 
release when both stimuli triggered the cells. 
In particular, PhNCS-COOH behaved as a stronger mast cell inhibitor 
(even at very low concentrations, 10 μM) in thapsigargin-induced 
degranulation. These results suggest that its inhibitory activity might 
be associated with the increase in cytosolic Ca++ derived from 
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internal storage rather than a major influx of external calcium 
(Graph 2 and 4). 
Ultimately, BMMC degranulation was induced by another stimulus. 
In particular, the extracellular nucleotide ATP, which is released by 
cells under stress conditions (inflammation, osmotic changes, anoxia, 
ischemia etc.), is also an important autocrine/paracrine mediator in 
mast cells. It can evoke exocytosis in response to an increase of 
intracellular Ca++[196] and mast cell degranulation[184]. Although ATP 
300 µM induced degranulation and renin release in BMMCs, PhNCS-
COOH slightly inhibited the exocytosis of granular contents, 
including β-hex and renin protein, albeit weak the inhibition resulted 
significant but without concentration-dependence. No effects were 
observed in the presence of NaHS (Graph 5). 
 
4.4.2. HMC-1 cells 
 
The administration of thapsigargin and A23187 elicited a significant 
degranulation in HMC-1 cell line due to the increased cytosolic Ca++. 
An evidence of degranulation is the release of β-hex and the 
simultaneous release of renin. In the presence of PhNCS-COOH, both 
thapsigargin- and A23187-induced degranulation markedly 
diminished, achieving a full abrogation of both mediators at 300 µM, 
indicating the modulatory role of this H2S-donor molecule in the 
calcium fluxes (Graph 6 and 7). Ultimately, incubation with ATP 100 
µM elicited degranulation and renin release, that was inhibited by 
PhNCS-COOH only at higher concentration (100 and 300 µM) (Graph 
8). 
 
4.5. Conclusion 
 
In conclusion, these results highlighted that FcεRI cross-linking on 
BMMCs elicits the release of enzymatically active renin protein. The 
angiotensin I-forming activity of the renin protein was inhibited by 
PhNCS-COOH. 
When mast cell degranulation and renin release was elecited by 
canonical degranulators such as calcium ionophore and thapsigargin, 
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which elicit mast cell renin release as a function of a mobilization of 
Ca++ influxes, the isothiocyanate molecule inhibiteds the process. 
Moreover, when ATP was exogenously added as pro-degranulative 
agent, PhNCS-COOH also inhibited mast cell degranulation and renin 
release but not in a concentration-dependent fashion, suggesting 
that activation of mast cells through purinergic receptors may not be 
a significant step in the H2S pathway.  
The present findings indicate that the selected H2S-donor and NaHS 
are able to reduce mast cell activation and renin release induced by 
different stimuli (antigen, A23187, thapsigargin and ATP). 
In conclusion, given the ubiquitous presence of mast cells[197] and the 
presence of angiotensinogen and angiotensin-converting enzyme in 
many tissues[198], renin release occurring during mast cell activation 
could result in local angiotensin II formation. Formed angiotensin II 
could cause many dysfunctions, particularly because this process is 
likely exacerbated in an impaired background. 
Thus, it can be hypothesized that this novel molecule may be useful 
in different conditions that lead to mast cell degranulation, such as 
cardiac mast cell activation due to ischemic injury. 
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Chapter 5 
 
Cardioprotective effects of 
H2S in rat and mouse hearts 
in I/R models 
 
5.1. H2S in ischemia/reperfusion and  consequent 
mast cell degranulation 
 
The encouraging results obtained in mast cell lines (RBL-2H3, BMMC 
and HMC-1) favoured the conclusion that the selected H2S-donor 
could offer a novel strategy in preventing mast cell degranulation, 
even when induced by I/R. Therefore, by inhibiting mast cell 
degranulation and renin release,  PhNCS-COOH could prevent the 
subsequent cardiac dysfunctions and arrhythmias. 
In this last part of the study, in order to evaluate whether the 
cardioprotective effects of H2S are due to a direct action on 
myocardial cells or to resident mast cells, ex vivo experiments have 
been carried out in isolated rat and mouse hearts models. Cardiac 
parameters were measured and evaluated in order to determine the 
degree of  cardioprotection.  
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5.2. Material and Methods 
5.2.1. Animals 
 
All the experimental procedures were carried out following the 
guidelines of the European Community Council Directive 86–609 and 
have been approved by the Ethic Committee for animal 
experimentation of the University of Pisa. 
 
5.2.2. Langendorff-perfused rat hearts 
 
Adult male Wistar rats, 260–350 g, were treated with an 
intraperitoneal injection of PhNCS-COOH (0.072-2.4 mg/kg) or 
vehicle (dimethyl sulfoxide; DMSO). When the mitoKATP blocker 5-
hydroxydecanoate (5-HD, 5 mg/Kg) was used, an intraperitoneal 
injection were done 20 minutes before the PhNCS-COOH i.p. 
injection. After 2 h, the rats were anaesthetised with sodium 
pentobarbital (100 mg/kg, i.p.) and heparinised (100 U, i.p.) to 
prevent blood clotting. The hearts were quickly excised and placed in 
Krebs solution (composition in mM: NaHCO3 25.0, NaCl 118.1, KCl 
4.8, MgSO4 KH2PO4 1.2, CaCl2 .2H2O 1.6, glucose 11.5) at 4°C, bubbled 
with 95% O2 O 1.6, 5% CO2 to stop contraction and reduce oxygen 
consumption. 
Rapidly, the ascending aorta was cannulated and the hearts mounted 
on a Langendorff apparatus. Then the hearts were perfused with 
Krebs solution (at 37°C and continuously bubbled with a gas mixture 
of 95% O2 and 5% CO2)at constant pressure (70-80 mmHg). The 
above procedure was completed within 2 min. A water-filled latex 
balloon, connected to a pressure transducer (Bentley Trantec, mod 
800, Ugo Basile, Comerio, Italy), was introduced into the left 
ventricle via the mitral valve; the volume of the balloon was adjusted 
to achieve a stable left ventricular end-diastolic pressure of 5-10 
mmHg during initial equilibration. The heart rate (HR) and left 
ventricular developed pressure (LVDP) were continuously 
monitored by a computerized Biopac system (Goleta, CA, USA) and 
the functional parameter of rate pressure product (RPP) was 
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calculated as RPP = HR x LVDP. Hearts showing severe arrhythmias 
or unstable LVDP and HR values during the pre-ischaemic phase 
were discarded. The coronary flow (CF) was volumetrically 
estimated by collecting the effluent over a measuring time of 5 min; 
CF was expressed as ml/min/g of heart weight. Coronary flow >28 
ml/min or <10 ml/min was considered as exclusion criteria for the 
hearts. At the end of the reperfusion period, the hearts were 
removed from the Langendorff apparatus and slices of the left 
ventricle were cut (2mm width) and immersed in an aqueous 
solution (1% w/v) of triphenyltetrazolium chloride (TTC, Sigma-
Aldrich) for 20 min and then in an aqueous solution of formaldehyde 
(20% v/v). After 24 h, the ventricular slices were photographed and 
analysed to identify the necrotic areas (visible as a white or light 
pink colour) and the healthy areas (visible as a strong red due to the 
TTC reaction). 
Previous experiments demonstrated that Langendorff-perfused rat 
hearts, not exposed to I/R, maintained stable levels of CF, LVDP and 
HR for at least 3 h. 
 
5.2.3. Data Analysis 
 
The amplitude of the maximal ischemic contracture (MIC) was 
evaluated in each experiment as a percentage of the pre-ischaemic 
LVDP. Moreover, the time (minutes) required to reach a half-
maximal ischaemic contracture (Thc) was calculated. To obtain the 
functional parameter of cardiac inotropism, the RPP recorded during 
the reperfusion was calculated and expressed as a percentage of the 
pre-ischaemic RPP. The CF measured during the reperfusion period 
was expressed as a percentage of the pre-ischaemic value. Finally, 
the ischaemic areas were evaluated planimetrically and expressed as 
a percentage of the whole area of the slices of the left ventricle 
(Ai/ALV). All the values are expressed as a mean ± standard error for 
6-8 different experiments. The effects of PhNCS-COOH on RPP and CF 
were statistically analysed by two-way analysis of variance. The 
effects of PhNCS-COOH on MIC, Thc and Ai/ALV were statistically 
analysed by one-way analysis of variance, followed by Bonferroni 
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post-test. P<0.05 was considered as indicative of significant 
difference. 
 
5.2.4. Langendorff-perfused mouse hearts 
 
Wild-type C57BL/6J mice (male, 10- to 12-week old, Jackson 
Laboratory, Bar Harbor, ME) were injected intraperitoneally with 4-
COOH-ITC 0.24 mg/Kg 2 h before the experiment. After the 
incubation time, mice were injected intraperitoneally with heparin 
(100 IU), anesthetized with CO2, and euthanized by cervical 
dislocation as approved by the Weill Cornell Medical College 
Institutional Animal Care and Use Committee. Hearts were isolated 
and transferred to a Langendorff apparatus (Radnoti, Monrovia, CA). 
The aorta was cannulated with a flanged 20-gauge stainless steel 
needle. The heart was perfused through the aorta in a retrograde 
mode at a constant pressure of 100 cm H2O with modified Krebs-
Henseleit (KH) buffer containing (mM): NaCl, 120; KCl, 4.7; CaCl2, 
2.5; MgSO4, 1.2; KH2PO4, 1.2; NaHCO3, 25; glucose, 11; pyruvic acid, 
2; and EDTA, 0.5. The perfusion fluid was bubbled with 95% O2 and 
5% CO2 at 37°C to give a pH of 7.4. After equilibration, all hearts 
were subjected to 30-minute ischemia(glucose- and pyruvic acid-
free KH buffer, 95% N2 + 5% CO2, and sodium dithionite) followed by 
30-minute reoxygenation (reperfusion) with KH buffer. 
Surface ECG was recorded and analyzed using Power 
Laboratory/8SP (AD Instruments; Colorado Springs, CO). Coronary 
flow was measured by timed collections of the effluent every 5 
minutes; samples were assayed for β-hex, renin and NE.  
 
5.2.5. Norepinephrine assay 
 
Norepinephrine was assayed in the coronary perfusate by high-
performance liquid chromatography coupled to electrochemical 
detection[199]. Perchloric acid and EDTA were added to samples to 
achieve final concentration of 0.01 N and 0.025%, respectively. The 
NE present in the effluent was adsorbed on acid-washed alumina 
adjusted at pH 8.6 with Tris-2% EDTA buffer (in agitation for 45 
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min) and then extracted in 150 μl of 0.1 N perchloric acid. This final 
sample aliquots were kept frozen until injected onto a 3µm ODS 
reverse-phase column (3.2 x 100 mm, Bioanalytical System, West 
Lafayette, IN) with an applied potential of 0.65 V. The mobile phase 
consisted of monochloroacetic acid (75 mM), Na2EDTA (0.5 mM), 
sodium octylsulfate (0.5 mM) and acetonitrile (1.5%) at pH 3.0. The 
flow rate was 1.0 ml/min. Dihydoxybenzylamine (DHBA) was added 
in each sample as an internal standard before alumina extraction and 
used for recovery calculation. The recovery of NE vas 77% and the 
detection limit was approximately 0.2 pmol. 
  
 5.2.6. β-hex assay in coronary effluent 
For β-hex measurements, samples of coronary effluent were 
concentrated 8- to 10-fold by centrifugal filtration (EMDMillipore). 
20 μl of the concentrated fraction from each sample were placed into 
a 96 well plate each as a triplicate and 50 μl of the β-hexosaminidase 
substrate (p-nitrophenyl-N-acetyl-β-d-glucosaminide 1.3 mg/ml 
dissolved in citrate buffer 0.1 M, pH 4.5)  was added and incubated 
for 90 min at 37° C. The reaction was stopped with 200 μl of glycine 
(0.2M pH 10.7). Optical density was read at 405 nm on a 
spectrophotometric plate reader using SoftMax Pro version 4.8 
(Molecular Devices, Sunnyvale,CA). β-hex release was expressed in 
terms of absorbance of the concentrated fraction, related to the total 
volume of the equivalent heart fraction. 
 
5.2.7. Renin assay in coronary effluent 
 
Renin release was measured by incubating 200 µl each sample of 
coronary effluent for 1.5 hours with porcine angiotensinogen (0.1 
mg/ml). Renin activity (angiotensin I formed) was then determined 
by by GammaCoat Plasma Renin Activity 125I Radioimmunoassay 
(DiaSorin, Stillwater, MN). The detection limit was approximately 
0.01 pmol. 
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5.2.8. Statistical Analysis 
 
Unpaired t-test was used throughout the study. P<0.05 was 
considered statistically significant. Data are expressed as means ± 
SEM. 
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5.3. Results 
 
The H2S-donor PhNCS-COOH, administrated via intraperitoneal 
injection at different doses (0.072, 0.24 and 0.72 mg/Kg), restored 
functional parameters such as cardiac inotropism (RPP and dP/dT) 
during the post-ischemic phase in rat hearts. In particular, in this 
dose range (0.072-0.72 mg/Kg) the H2S-donor induced 
cardioprotective effects, although it did not evoke significant 
improvements in post-ischemic coronary flow (CF %).  
Cardioprotection was also confirmed by morphological data, where 
the values of injured areas of the left ventricle (Ai/Alv, ischemic 
area/total area of left ventricle expressed in percentage), indicated a 
cardioprotective role of PhNCS-COOH, in a concentration-related 
manner.  
An increased dose of PhNCS-COOH (2.4 mg/Kg) was also tested, but 
it did not elicit the recovery of the functional parameters of RPP, 
dP/dt and CF, during 120 min of reperfusion time following 30 min 
of global ischemia. Even in the morphologic assay, the higher dose 
did not prevent cells death after ischemia (Graph 1). Notably, also 
the MIC and the Thc values are perfectly correlated to functional and 
morphologic data (Graph 2). 
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Graph 1. PhNCS-COOH elicits cardioprotective effects in I/R injury. 
Correlation between functional and morphological data. The curves 
describe the recovery of the functional parameters of RPP, dP/dt and CF 
during 120 min of reperfusion time following 30 min of global ischemia, in 
Langendorff-perfused hearts isolated from vehicle-treated or PhNCS-
COOH-treated rats. The vertical bars represent the standard errors (n = 6-
8). The histograms represent the values of injured areas, expressed as a % 
of the whole left ventricle (Ai/Alv %) from vehicle-treated or PhNCS-
COOH-treated rats submitted to the I/R cycle. 
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Graph 2. Representative bars of MIC and Thc expressed in percentage. 
 
The dose 0.24 mg/Kg was selected for further studies. 5-
hydroxydecanoate (5-HD, 5 mg/Kg), a selective inhibitor of mitoKATP, 
was used to evaluate a potential effect of PhNCS-COOH on this kind 
of mitochondrial channels. In line with the widely recognized 
involvement of H2S in ATP-sensitive potassium channels, the effect of 
the H2S-donor PhNCS-COOH was antagonized by the mitoKATP 
blocker 5-HD (Graph 3). As shown in the figure, the three 
parameters recorded were antagonized and were comparable to the 
vehicle values (I/R). Moreover, also in this case the morphologic 
assay resulted to be coherent with the functional data. Indeed, the 
areas damaged by I/R were wider in the presence of 5-HD (Graph 
3). Again, the reduction of MIC % and the increase in Thc was 
antagonized by the mitoKATP blocker (Graph 4). 
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Graph 3. Cardioprotective effect of PhNCS-COOH 0.24 mg/Kg: antagonism 
by 5-HD. Correlation between functional and morphological data. Time-
course of the rate pressure product (RPP) values, dP/dT and CF, recorded 
during the reperfusion and expressed as a percentage of the pre-ischaemic 
respective values, in the hearts isolated from vehicle-treated, PhNCS-
COOH-treated and PhNCS-COOH + 5-HD-trated rats and submitted to the 
ischemia/reperfusion cycle.  
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Graph 5. Representative bars of MIC and Thc expressed in percentage. 
 
In order to evaluate whether the cardioprotective role of this 
molecule might correlate with an anti-degranulative effect in 
resident mast cell, the levels of β-hex (in terms of absorbance) were 
measured from the coronary effluent collected from Langendorff-
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perfused rat hearts. The results clearly indicated that mast cell 
degranulation is not inhibited by PhNCS-COOH during the I/R 
process (Graph 6). Instead of a protective role, with a higher 
concentration of the compound an increase in the degranulation of 
resident mast cells occurred, suggesting that higher doses evoke 
toxic effects (Graph 6, green bar). 
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Graph 6. β-hex released by resident mast cells after I/R injury in the presence or 
not of different doses of PhNCS-COOH. β-hex (marker of MC degranulation) from 
Langendorff-perfused murine hearts was measured in overflow fractions, collected 
immediately after the reperfusion time. Data are expressed as means ± SEM. 
 
These first results brought to the further investigation of different 
cardiac parameters measured in ischemic-reperfused hearts in a 
murine model.  
Thus, the next step regarded whether PhNCS-COOH might have an 
impact in the reduction of I/R damage and whether it could inhibit 
renin release from resident mast cells. The results showed that when 
Langendorff-perfused murine hearts were subjected to 30-minute 
ischemia, followed by 30-minute reoxygenation, renin and 
norepinephrine (NE) largely increased during the first 5 min of 
reperfusion and a development of ventricular 
tachycardia/fibrillation (VT/VF) also occurred (Graph 7). The 
intraperitoneal injection of PhNCS-COOH, significantly diminished 
NE release as well as the duration of VT/VF, but not renin release 
from mast cells (Graph 7). 
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Graph. 7. I/R in Langendorff-perfused mouse hearts ex vivo: effects of PhNCS-
COOH. I/R induced NE and renin release in the coronary overflow and evoked a 
prolonged arrhythmia (VT/VF) duration. These effects are evaluated in the 
presence of PhNCS-COOH. NE release in the coronary overflow and duration of 
VT/VF in ischemic conditions were significantly reduced, but not the release of 
renin.  Bars represent means ± SEM of renin and NE overflows during the first 5 
min of reperfusion and duration of VT/VF measured during the entire 30 min of 
reperfusion. *P , 0.05 vs. I/R by unpaired t-test.  
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To corroborate the preliminary interesting data, β-hex release was 
measured in coronary effluent from Langendorff-perfused murine 
hearts. Mice were previously injected with 0.24 mg/Kg of PhNCS-
COOH, and the hearts were excised and mounted in a Langendorff 
apparatus. Coronary effluent was collected during the entire 
experiment after inducing I/R and β-hex was measured in each 
perfusate collected. In I/R-damaged mouse hearts, resident mast cell 
degranulation occurred as shown by an increase in the coronary 
overflow of β-hex. Finally, no inhibition of resident mast cell 
degranulation occurred when mice were injected with the H2S-donor 
(Graph. 8). 
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Graph 8. Release of β-hex in the perfusate fractions from ex vivo mice hearts. β-hex 
(marker of MC degranulation) from Langendorff-perfused murine hearts was 
measured in overflow fractions, collected every 5 min after reperfusion. Data 
are expressed as means ± SEM. N=3 to 7 hearts. OD, optical density at 405 nm. 
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5.3. Discussion 
 
As literature suggested, H2S activity can modulate and reduce I/R 
injury; for example, NaHS was observed to limit the size of infarction 
induced by left coronary artery ligation. In addition, NaHS also has 
been shown to protect cultured myocardial cells against hypoxia-
induced cell death[200]. 
The H2S released from the novel molecule PhNCS-COOH, showed 
cardioprotective effects both in rat and mouse hearts in I/R models. 
Different doses of the compound were used, but only the 0.24 mg/Kg 
was selected for further experiments in ex vivo models. Moreover, 
the highest dose of PhNCS-COOH (2.4 mg/Kg) injected in rats seems 
to produce opposite effects, suggesting a possible toxicity. This 
hypothesis is also confirmed by the increased levels of β-hex in the 
coronary overflow.  
When 0.24 mg/Kg of the H2S-donor was injected in mice, the 
Langendorff-perfused hearts, exposed  to 30 min of ischemia and 30 
min of reoxygenation, led to a reduction in arrhythmias (VT/VF) and 
NE release, but not in renin. This result corroborated the preliminary 
data obtained in rat hearts, suggesting that the cardioprotective role 
of the isothiocyanate is not correlated to mast cell degranulation and 
inhibition of renin release.  
The cardioprotection induced by the H2S-donor might be due to the 
activation of specific channels, such as the mitoKATP channels. In 
order to demonstrate this hypothesis, the specific mitoKATP blocker 
5-HD was pre-injected in the presence of PhNCS-COOH. The 
antagonism observed on the anti-ischemic effect of the H2S-donor 
was perfectly clear, consolidating the hypothesis of a possible 
mechanism on mitochondrial ion channels.  
 
5.4. Conclusions 
 
Following in the footsteps of nitric oxide and carbon monoxide, 
hydrogen sulfide is rapidly emerging as a critical signaling molecule. 
Although the complete actions of this gas remain under 
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investigation, the therapeutic options relating to the cardiovascular 
system are extremely promising. Future research will delineate the 
means of utilizing this molecule effectively in various cardiovascular 
disease states. 
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